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SUBSTRATE DELIVERY OF EMBEDDED
LIPOSOMES

ments , the ratio of PLL / SPS is from about 1 to about 1.5 . In

CROSS - REFERENCE TO RELATED

APPLICATIONS

.

5

This application is a National Stage Application under 35

U.S.C. § 371 and claims the benefit of International Appli
cation No. PCT /US2016 / 047042, filed Aug. 15 , 2016 , which

claims the benefit of U.S. Provisional Application Ser. No. 10
62 /205,473 , filed Aug. 14 , 2015 , the disclosure of which is
incorporated herein by reference in its entirety.
TECHNICAL FIELD

This invention relates to compositions useful for localized
and sustained release of therapeutic agents, and more par

15

ticularly to functionalized liposomes embedded in a polyelectrolyte multilayer.

20

BACKGROUND

The engineering of drug delivery platforms facilitating

spatial and temporal release of a therapeutic is one of the key
challenges in biomedical research that can ultimately lead to 25
society - wide improvement in disease management. Specifically, the drug delivery kinetics is particularly relevant when
it is necessary to achieve effective dose and spatiotemporal
release kinetics of the therapeutic agent at the intended site

of injury. Delivery via immobilization of the therapeutic 30

cargo to a solid platform demonstrates higher translatable
success compared to delivery using the free “ bolus ” form by
overcoming unfavorable burst kinetics, toxic offsite effects,
and efficacy reduction due to systemic dilution .

35

SUMMARY

The present application provides, inter alia , a composition
i ) one or more hyaluronic acid conjugated liposomes ; and
ii ) a polyelectrolyte multilayer.
In some embodiments, the polyelectrolyte multilayer
comprises one or more independently selected polycationic
polymers. In some embodiments, the polyelectrolyte multilayer comprises one polycationic polymer. In some embodiments, each of the polycationic polymers is independently
selected from the group consisting of poly - D - lysine ( PDL ) ,
poly - L - lysine ( PLL) , poly ( diallyl dimethylammonium chloride) ( PDAC ), linear polyethylene imine ) ( LPEI ) , poly
( allyl-amine hydrochloride ) (PAH ), chitosan (CHI ) , a poly
( ß - amino ester ), and polyarginine.
In some embodiments , the polyelectrolyte multilayer
comprises one or more independently selected polyanionic
polymers. In some embodiments, the polyelectrolyte multilayer comprises one polyanionic polymer. In some embodiments , each of the polyanionic polymers is independently
selected from the group consisting of poly ( sodium styrene
sulfonate ) ( SPS ) , poly ( anetholesulfonic acid ) (PAS ), poly
( acrylic acid) (PAA ), poly ( sodium vinylsulfonate ) ( PVS ) ,
graphene oxide (GO ) , dextran sulfate, collagen, and
hyaluronic acid ( HA) .
In some embodiments, at least one of the polycationic
polymers is poly - L - lysine (PLL ) and at least one of the
polyanionic polymers is poly ( sodium styrene sulfonate )
( SPS ) . In some embodiments, the ratio of PLL/ SPS is from
comprising:

about 1 to about 2. In some embodiments, the ratio of
PLL/ SPS is from about 1 to about 1.75 . In some embodi-

some embodiments, the polyelectrolyte multilayer com
prises from about 2 to about 10 monolayers of PLL . In some
embodiments, the polyelectrolyte multilayer comprises from
about 2 to about 8 monolayers of PLL . In some embodi
ments, the polyelectrolyte multilayer comprises from about
2 to about 6 monolayers of PLL . In some embodiments, the
polyelectrolyte multilayer comprises from about 3 to about
5 monolayers of PLL . In some embodiments, the polyelec
trolyte
multilayer
from about, the
2 topolyelectro
about 10
monolayers
of SPS .comprises
In some embodiments
lyte multilayer comprises from about 2 to about 8 mono
layers of SPS . In some embodiments, the polyelectrolyte
multilayer comprises from about 2 to about 6 monolayers of
SPS . In some embodiments, the polyelectrolyte multilayer
comprises from about 3 to about 5 monolayers of SPS . In
some embodiments, the polyelectrolyte multilayer com
prises about 5 monolayers of PLL and about 4 monolayers
of SPS .
In some embodiments, the hyaluronic acid is covalently
bonded to the liposome . In some embodiments, the
hyaluronic acid is conjugated on the surface of the liposome
In some embodiments, the liposome comprises a hydrophilic
core and a hydrophobic lipid bilayer.
In some embodiments, the liposome further comprises
one or more therapeutic agents. In some embodiments, each
of the therapeutic agents is independently localized in the
hydrophilic core or hydrophobic lipid bilayer of the lipo
some . In some embodiments, each of the therapeutic agents
is independently selected from the group consisting of a
chemotherapeutic agent, a silencing RNA , a steroid , an
immunosuppressant, an anti -microbial agent, an anti - fungal
agent, an anti - inflammatory agent, a gene therapy agent, an
anti -angiogenic agent, and aa CRISPR /Cas9 agent. In some
embodiments, at least one of the therapeutic agents is a
chemotherapeutic agent or a silencing RNA .
In some embodiments, at least one of the chemothera
peutic agents is selected from the group consisting of an
alkylating agent, an anti-metabolite , an anti-tumor antibi
otic , a topoisomerase inhibitor, a mitotic inhibitor, a plant
alkaloid
, a microtubule inhibitor, a DNA linking agent, an
immunotherapeutic agent, and a differentiating agent In
some embodiments, at least one of the chemotherapeutic
agents is an anti - tumor antibiotic . In some embodiments, at
least one of the chemotherapeutic agents is doxorubicin .
In some embodiments, the liposome further comprises a
fluorescently tagged lipid . In some embodiments, the fluo
rescently tagged lipid is a fluorescently tagged cholesterol.
In some embodiments, the liposome further comprises a
targeting moiety. In some embodiments , the targeting moi
ety is conjugated to the hyaluronic acid . In some embodi
ments, the targeting moiety is selected from the group
consisting of an antibody, a small molecule , a polypeptide ,
an aptamer, a folate, a transferrin , a glycoprotein , an integ
rin , and a carbohydrate.
In some embodiments, the composition further comprises
an additional polyelectrolyte multilayer.
In some embodiments , the additional polyelectrolyte mul
tilayer comprises one or more independently selected poly
cationic polymers . In some embodiments, the additional
polyelectrolyte multilayer comprises one polycationic poly
mer. In some embodiments , each of the polycationic poly
mers is independently selected from the group consisting of
poly - D - lysine ( PDL ) , poly - L - lysine ( PLL ), poly (diallyl
dimethylammonium chloride ) (PDAC ) , linear poly (ethylene

40
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imine ) ( LPEI ) , poly ( allyl -amine hydrochloride) (PAH ), chi
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In some embodiments, the additional polyelectrolyte multilayer comprises one or more independently selected polyanionic polymers. In some embodiments, the additional
polyelectrolyte multilayer comprises one polyanionic polymer. In some embodiments, each of the polyanionic polymers is independently selected from the group consisting of
poly ( sodium styrene sulfonate) ( SPS ) , poly (anetholesulfonic acid) ( PAS ), poly (acrylic acid ) ( PAA ), poly ( sodium
vinylsulfonate) (PVS ) , graphene oxide ( GO ) , dextran sulfate, collagen , and hyaluronic acid ( HA ) .
In some embodiments, at least one of the polycationic
polymers is poly - L - lysine (PLL ) and at least one of the
polyanionic polymers is poly ( sodium styrene sulfonate )
( SPS ) .
In some embodiments , the polyelectrolyte multilayer is
prepared using sequential deposition of the polycationic
polymer and the polyanionic polymer. In some embodiments , the additional polyelectrolyte multilayer is prepared
using sequential deposition of the polycationic polymer and
the polyanionic polymer.
In some embodiments, the one or more hyaluronic acid
conjugated liposomes is deposited onto the polyelectrolyte
multilayer. In some embodiments, the additional polyelectrolyte multilayer is deposited onto the one or more
hyaluronic acid conjugated liposomes ..
In some embodiments, the composition is further deposited onto a substrate . In some embodiments, the substrate is
selected from the group consisting of aa medical device , a
tablet , a capsule, a bandage, a gel , and a nanoparticle . In
some embodiments, the medical device is selected from the
group consisting of a stent, a catheter, a syringe , a needle , a

the polyelectrolyte multilayer comprises one or more
independently selected polanionic polymers, and
each of the polyanionic polymers is independently
selected from the group consisting of poly ( sodium styrene
sulfonate) ( SPS ) , poly (anetholesulfonic acid) ( PAS ), poly
( acrylic acid) (PAA ), poly ( sodium vinylsulfonate ) ( PVS ) ,
graphene oxide (GO ) , dextran sulfate , collagen, and
hyaluronic acid ( HA) .
In some embodiments:
the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents;
the polyelectrolyte multilayer comprises a polyanionic
polymer selected from the group consisting of poly ( sodium
styrene sulfonate ) ( SPS ) , poly (anetholesulfonic acid) (PAS ),
poly (acrylic acid ) ( PAA ), poly ( sodium vinylsulfonate )
( PVS ) , graphene oxide ( GO ) , dextran sulfate, collagen , and
hyaluronic acid ( HA) .
In some embodiments :
the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ;
the polyelectrolyte multilayer comprises one or more
independently selected polycationic polymers and one or
more independently selected polyanionic polymers;
wherein each of the polycationic polymers is indepen
dently selected from the group consisting of poly - D - lysine
(PDL ) , poly - L - lysine ( PLL ) , poly (diallyl dimethylammo
nium chloride) (PDAC ) , linear poly ( ethylene imine) (LPEI ) ,
poly ( allyl - amine hydrochloride) (PAH ), chitosan ( CHI ) , a
poly ( ß - amino ester ), and polyarginine; and
each of the polyanionic polymers is independently
selected from the group consisting of poly ( sodium styrene
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microneedle , a medical implant, a metal rod , a cardiac pace

maker, a surgical staple, a surgical suture, a eedle, and a

balloon .

In some embodiments :

the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ; and
the polyelectrolyte multilayer comprises one or more

( acrylic acid ) (PAA ), poly (sodium vinylsulfonate ) ( PVS ) ,
graphene oxide (GO ) , dextran sulfate , collagen, and
35 hyaluronic acid ( HA) .

independently selected polycationic polymers.

40
the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ;
the polyelectrolyte multilayer comprises one or more
independently selected polycationic polymers; and
each of the polycationic polymers is independently 45
selected from the group consisting of poly - D - lysine ( PDL ) ,
poly - L - lysine ( PLL) , poly ( diallyl dimethylammonium chloride) (PDAC ) , linear poly ( ethylene imine) (LPEI ) , poly
( allyl -amine hydrochloride) (PAH ), chitosan (CHI), a poly
( -amino ester ), and polyarginine.
50
In some embodiments :
the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ;
the polyelectrolyte multilayer comprises a polycationic
polymer selected from the group consisting of poly - D - lysine 55
(PDL ), poly - L - lysine ( PLL ) , poly ( diallyl dimethylammonium chloride) (PDAC ) , linear poly ( ethylene imine) ( LPEI ) ,
In some embodiments:

poly (allyl -amine hydrochloride) ( PAH ), chitosan ( CHI ) , a
poly ( ß - amino ester ), and polyarginine.

60
the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ; and
the polyelectrolyte multilayer comprises one or more
independently selected polyanionic polymers .
65
In some embodiments :
the one or more hyaluronic acid conjugated liposomes
In some embodiments :

further comprise one or more therapeutic agents;

sulfonate) (SPS), poly ( anetholesulfonic acid ) (PAS ), poly

In some embodiments:
the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ;
the polyelectrolyte multilayer comprises one polycationic
polymer and one polyanionic polymer;
wherein the polycationic polymer is selected from the
group consisting of poly - D - lysine ( PDL ) , poly - L - lysine
(PLL ) , poly (diallyl dimethylammonium chloride) ( PDAC ) ,
linear polyethylene imine ) ( LPEI ) , poly ( allyl-amine hydro
chloride ) ( PAH ), chitosan ( CHI ) , a poly ( ß -amino ester ), and
polyarginine; and
the polyanionic polymer is selected from the group con
sisting of poly ( sodium styrene sulfonate ) ( SPS ) , poly (anet
holesulfonic acid ) ( PAS ) , poly (acrylic acid ) ( PAA ) , poly
( sodium vinylsulfonate) (PVS ), graphene oxide (GO ) ,
dextran sulfate , collagen, and hyaluronic acid ( HA) .
In some embodiments, at least one of the polycationic
polymers is poly -L - lysine (PLL ) and at least one of the
polyanionic polymers is poly ( sodium styrene sulfonate )
( SPS ) . In some embodiments, the ratio of PLL/ SPS is from
about 1 to about 2. In some embodiments, the ratio of
PLL / SPS is from about 1 to about 1.75 . In some embodi
ments, the ratio of PLL /SPS is from about 1 to about 1.5 . In
some embodiments, the polyelectrolyte multilayer com
prises from about 2 to about 10 monolayers of PLL . In some
embodiments , the polyelectrolyte multilayer comprises from
about 2 to about 8 monolayers of PLL . In some embodi
ments, the polyelectrolyte multilayer comprises from about
2 to about 6 monolayers of PLL . In some embodiments, the
polyelectrolyte multilayer comprises from about 3 to about
5 monolayers of PLL . In some embodiments, the polyelec
trolyte multilayer comprises from about 2 to about 10
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monolayers of SPS . In some embodiments, the polyelectro- rod , a cardiac pace maker, a surgical staple, a surgical suture,
lyte multilayer comprises from about 2 to about 8 mono- a needle , and a balloon . In some embodiments, the device
layers of SPS . In some embodiments, the polyelectrolyte further comprises an additional polyelectrolyte multilayer
multilayer comprises from about 2 to about 6 monolayers of deposited onto the one or more hyaluronic acid conjugated
SPS . In some embodiments, the polyelectrolyte multilayer 5 liposomes.
comprises from about 3 to about 5 monolayers of SPS . In
The present application further provides a tablet coated
some embodiments, the polyelectrolyte multilayer com with a composition comprising:
prises about 5 monolayers of PLL and about 4 monolayers
i ) one or more hyaluronic acid conjugated liposomes ; and
of SPS .
ii
polyelectrolyte multilayer.
In some embodiments, the liposome further comprises a 10 In) asome
embodiments, the tablet further comprises an
targeting moiety. In some embodiments, the targeting moi additional polyelectrolyte
multilayer deposited onto the one
ety is conjugated to the hyaluronic acid . In some embodi or more hyaluronic acid conjugated
liposomes .
ments, the targeting moiety is selected from the group
The
present
application
further
provides
a method of
consisting of an antibody, a small molecule , a polypeptide, preparing a composition provided herein, the method
com
an aptamer, a folate, a transferrin , a glycoprotein , an integ- 15 prising:
rin , and a carbohydrate.
In some embodiments , the composition further comprises
i ) sequentially depositing two or more polyionic polymers
an additional polyelectrolyte multilayer. In some embodi to form the polyelectrolyte multilayer ; and
ments, the additional polyelectrolyte multilayer comprises
ii ) depositing the one or more hyaluronic acid conjugated
one or more independently selected polycationic polymers. 20 liposomes onto the polyelectrolyte multilayer.
In some embodiments, the additional polyelectrolyte multiIn some embodiments, at least one of the polyionic
layer comprises one polycationic polymer. In some embodi- polymers is a polycationic polymer and at least one of the
ments, each of the polycationic polymers is independently polyionic polymers is polyanionic polymer. In some
selected from the group consisting of poly - D - lysine ( PDL ) , embodiments, the sequential depositing comprises sequen

poly - L - lysine ( PLL) , poly ( diallyl dimethylammonium chlo- 25 tial depositing of the two or more polyionic polymers onto

ride) (PDAC ), linear poly ( ethylene imine) ( LPEI ) , poly
( allyl -amine hydrochloride) (PAH ), chitosan (CHI ) , a poly

(B - amino ester ), and polyarginine. In some embodiments,
the additional polyelectrolyte multilayer comprises one or

the surface of a substrate.

In some embodiments, the substrate is selected from the

group consisting of a medical device , a tablet, a capsule , a
bandage , a gel , and a nanoparticle . In some embodiments,

more
independently selected polyanionic polymers. In some 30 the medical device is selected from the group consisting of
embodiments, the additional polyelectrolyte multilayer a stent, a catheter, a syringe , a needle , a microneedle , a
comprises two independently selected polyanionic poly
medical implant, a metal rod, a cardiac pace maker, a
surgical staple , a surgical suture, a needle , and a balloon .
embodiments, step ii ) comprises contacting the
poly ( sodium styrene sulfonate) ( SPS ) , poly (anetholesulfo- 35 oneInorsome
more hyaluronic acid conjugated liposomes with the
nic acid ) (PAS ), poly (acrylic acid ) ( PAA ), poly (sodium
vinylsulfonate) (PVS ) , graphene oxide ( GO ) , dextran sul- polyelectrolyte multilayer at about room temperature .
fate, collagen, and hyaluronic acid (HA) . In some embodiThe present application further provides a method of
ments, at least one of the polycationic polymers is poly - L preparing a composition provided herein , the method com
mers . In some embodin ats, each of the polyanionic poly
mers is independently selected from the group consisting of

lysine (PLL) and at least one of the polycationic polymers is 40 prising:

i ) sequentially depositing two or more polyionic polymers
poly ( sodium styrene sulfonate ) ( SPS ) .
In some embodiments, the polyelectrolyte multilayer is to form the polyelectrolyte multilayer;
prepared using sequential deposition of the polycationic
ii ) depositing the one or more hyaluronic acid conjugated
polymer and the polyanionic polymer. In some embodi- liposomes onto the polyelectrolyte multilayer; and
ments, the additional polyelectrolyte multilayer is prepared 45 iii ) depositing the additional polyelectrolyte multilayer
using sequential deposition of the polycationic polymer and onto the one or more hyaluronic acid conjugated liposomes .
the polyanionic polymer. In some embodiments, the one or
In some embodiments, the sequential depositing com
more hyaluronic acid conjugated liposomes is deposited prises sequential depositing of the two or more polyionic
onto the polyelectrolyte multilayer. In some embodiments, polymers onto the surface of a substrate .
the additional polyelectrolyte multilayer is deposited onto 50 In some embodiments, step ii ) comprises contacting the
the one or more hyaluronic acid conjugated liposomes .
one or more hyaluronic acid conjugated liposomes with the
In some embodiments , the composition is further depos- polyelectrolyte multilayer at about room temperature .
ited onto a substrate . In some embodiments, the substrate is
In some embodiments, the contacting is performed from
selected from the group consisting of a medical device , a about 1 to about 10 hours . In some embodiments, the

tablet, a capsule, a bandage, a gel, and a nanoparticle. In 55 contacting is performed from about 2 to about 5 hours.
some embodiments, the medical device is selected from the
microneedle , a medical implant, a metal rod, a cardiac pace

group consisting of a stent, a catheter, a syringe , a needle , a

In some embodiments, at least one of the polyionic
polyionic polymers is polyanionic polymer. In some

polymers is a polycationic polymer and at least one of the

maker, a surgical staple, a surgical suture , a needle , and a embodiments, each of the polycationic polymers is indepen
balloon .
60 dently selected from the group consisting of poly - D - lysine
The present application further provides a device coated ( PDL ) , poly - L - lysine ( PLL ), poly (diallyl dimethylammo
with a composition comprising:
nium chloride) (PDAC ) , linear poly ( ethylene imine) (LPEI ) ,
i ) one or more hyaluronic acid conjugated liposomes ; and poly ( allyl - amine hydrochloride) (PAH ), chitosan ( CHI ) , a
ii ) a polyelectrolyte multilayer.
poly ( ß - amino ester ), and polyarginine. In some embodi
In some embodiments, the device is a medical device 65 ments, each of the polyanionic polymers is an independently
selected from the group consisting of a stent, a catheter, a selected from the group consisting of poly ( sodium styrene
syringe, a needle , a microneedle , a medical implant, a metal sulfonate) ( SPS ) , poly (anetholesulfonic acid) ( PAS ), poly
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( acrylic acid) ( PAA ), poly ( sodium vinylsulfonate ) ( PVS ) ,
FIG . 2C shows a representative fluorescent recovery after
graphene oxide (GO ) , dextran sulfate , collagen, and photo bleaching (FRAP ) analysis pre- and post- the addition
of the capping layer at 10 min
hyaluronic acid ( HA) .
The present application further provides a method for 5 FIG . 2D shows a representative fluorescent recovery after
controlled release of one or more therapeutic agents, com- photo bleaching ( FRAP ) analysis pre- and post- the addition
prising administering to a subject a composition provided of the capping layer at 0 min , 10 min , and 30 min .
herein . The present application further provides a method for
FIG . 3A shows representative data from an affinity assay
delayed release of one or more therapeutic agents, compris- for HALNP absorption on (PLL/ SPS ) 4.5 and ( PLL/ SPS ) 4
ing administering to a subject a composition provided substrates to determine the optimum conditions for nanopar
herein . In some embodiments, the method is performed ex 10 ticle deposition.
vivo . In some embodiments, the method is performed in
FIG . 3B shows a representative saturation curve analysis
vivo .
of
lipid loaded on ( PLL/ SPS )4.5 per square centimeter
The present application further provides a method of as total
a function of total lipid added during the three hour
treating a disease in a subject in need thereof, comprising incubation
.
administering to the subject a composition provided herein . 15 FIG . 3Ctime
shows
a representative HALNP nanocarrier
In some embodiments , the composition releases the one or release profile from
the non - capped [ ( PLL / SPS ) 4.5
more therapeutic agents as a controlled release . In some
(
HALNP
)
]
and
capped
[ (PLL/ SP S ) 4.5 ( HALNP) (PLL/
embodiments, the composition releases the one or more

therapeutic agents as a delayed release . In some embodi- SPS ) 2.5 ] HALNP - PEM platforms.
ments, the administration comprises contacting a diseased 20 FIG . 4A shows 21 MT- 1 metastatic breast cancer cell
cell with a composition provided herein . In some embodi- uptake of fluorescently conjugated HALNPs from the
ments, the method is performed ex vivo . In some embodi- embedded PEM system with capping layer and HA - LNP
ments, the method is performed in vivo . In some embodi- bolus system as a function of time [ (PLL/ SPS )4.5 (HALNP )
ments, the disease is a cancer selected from the group (PLL /SPS ), 5 ) using flow cytometry analysis (percent cell
consisting of pancreatic cancer , bladder cancer, brain cancer, 25 population FITC positive uptake between the HALNP - PEM
breast cancer, colon cancer, endometrial cancer, gastrointes- and HA - LNP bolus system) . # denotes significance between
tinal cancer , a hematological cancer, liver cancer , lung a specific sample type and the preceding time point follow
cancer, prostate cancer, skin cancer, stomach cancer, and ing the same significance scale as the stars ).
renal cancer. In some embodiments , the cancer is breast

FIG . 4B shows 21 MT- 1 metastatic breast cancer cell

Unless otherwise defined , all technical and scientific

embedded PEM system with capping layer as a function of
time [ ( PLL / SPS ) 4.5 ( HALNP ) ( PLL / SPS ) 2,5 ) using flow
cytometry analysis ( per cell fluorescence directly comparing

cancer
. In some embodiments, the cancer is brain cancer . In 30 uptake of fluorescently conjugated HALNPs from the
some embodiments, the brain cancer is glioblastoma .

terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which this
invention
belongs . Methods and materials are described
herein for use in the present invention ; other, suitable

35 nanoparticle
uptake between the HALNP -PEM and HA
LNP bolus systems ( * P <0.05 , ** P <0.005 ; n=3 ) ) . # denotes

significance between a specific sample type and the preced
ing time point following the same significance scale as the
The materials, methods, and examples are illustrative only stars
).
and not intended to be limiting . All publications, patent
applications, patents, sequences , database entries, and other 40 FIG . 4C shows representative imagines of aa visual inves
references mentioned herein are incorporated by reference in tigation of nanoparticle intracellular delivery on the
their entirety. In case of conflict, the present specification , HALNP - PEM platform using Phase Contrast and Fluores
cent Microscopy.
including definitions, will control.
FIG . 5 shows results of a doxorubicin potency assay
DESCRIPTION OF DRAWINGS
45 comparison between Free Dox , DOX encapsulated in HAL
NPs (HALNPDOX ) in the bolus form , and HALNPDOX
FIG . 1A shows a representative UV spectrum analysis of nanoparticles embedded into the PEM platform (HALNP
methods and materials known in the art can also be used .

bilayer deposition .
DOX - PEM) . Standard MTT protocol was used to determine
FIG . 1B shows representative UV absorbance readings the % viable cells at 24 hours .
( 220 nm , characteristic for SPS ) as a function of bilayer 50 FIG . 6 shows DOX release profile from the non -capped
addition to demonstrate base construction.
[ (PLL /SPS ) 4.5 (HALNP )] and capped [ (PLL /SPS ) 4.5
FIG . 1C shows representative atomic force microscopy (HALNP ) (PLL/ SPS ) 2,5 ] HALNP - PEM platforms as a func
(AFM ) images of the (PLL/ SPS )4.5 base platform via height tion of time utilizing the natural fluorescence of the chemo
( i ) and phase contrast (ii ) analysis to visually demonstrate a therapeutic agent for quantification.
uniform surface ideal for nanoparticle deposition . Scale bar 55 FIG . 7A shows phase contrast and fluorescent microscopy
for AFM is 1
images of 21 MT- 1 metastatic breast cancer cells adhered to

FIG . 2A shows preferential deposition of hyaluronic acid the HALNP - PEM system to visually probe both the tempo
covalently functionalized liposomes ( HALNPs ) on poly -L- ral and spatial release of the HALNP nanocarrier. Capillary
lysine (PLL ) over poly ( sodium styrene sulfonate) ( SPS ) force lithography (CFL ) was used to pattern PLL and create
topped surfaces. Capillary Force Lithography ( CFL) was 60 long range order of fluorescently tagged HALNP .
used to create PLL patterns on ( PLL/ SPS )4 and to demonFIG . 7B shows phase contrast and fluorescent microscopy
strate the level of spatial control for nanoparticle adsorption. images of 21 MT- 1 metastatic breast cancer cells adhered to
FIG . 2B shows a representative fluorescent recovery after the HALNP - PEM system to visually probe both the tempo
photo bleaching ( FRAP ) analysis pre- and post- the addition ral and spatial release of the HALNP nanocarrier. Capillary
of the capping layer at 0 and 10 min . The arrows point to 65 force lithography (CFL ) was used to pattern PLL and create
particles that have moved during the experimental time long range order of HALNPDOX patterns via preferential
nanoparticle adsorption .
lapse .
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FIG . 8A shows representative Transmission Electron

Microscopy ( TEM ) images using the negative stain method
with 2 % phosphotungstic acid . Scale bars are 250 nm .
FIG . 8B shows particle size distribution data for repre5
sentative LNP and HALNP nanoparticle systems .

n=4 ; # denotes significance between LF2K and HA - LNP at

the analogous miR125a - 5p concentration - following the
same significance level designations as the stars ( * ) . The
AACt method was used to determine the change in mRNA
expression
FIGS . 13A - 13B show Western blot analysis of the HER2
FIG . 9A shows Western Blot data of CD44 protein expres
sion in (i ) MCF10A (normal breast tissue ) , (ii ) SKBR3 pathway in 21MT- 1 cells 72 hours following transfection
miR125a - 5p . FIG . 13A shows Western blots and
( HER2 + invasive breast cancer ), and ( iii ) 21MT- 1 (HER2 + with
molecular
weights of probed proteins. FIG . 13B shows
metastatic breast cancer ) cell lines . 20 kDa FD model drug quantification
the Western Bblot data ( * P <0.05 ,
systems were utilized in two distinct forms: ( 1 ) encapsulated 10 ** P < 0.005, ***ofP <0.0001
; # denotes significance between
inside the aqueous core of HALNPs and (2 ) naked drug (i.e. LF2K 50 pmol and HALNP
miR 50 pmol , # =P <0.05 ,
free form drug, not conjugated with LNPs ) .
##
=
P
<
0.005
;
n
=
3
)
.
Normalization
controls used : GAPDH
FIG . 9B shows fluorescent and phase contrast microscopy for HER2 , PI3K and Ki67 , total AKT
for PAKT, and total
images of HALNP mediated FD delivery to three breast cell

ERK1 / 2 for PERK1 / 2 .
FIGS . 14A - 14D show HALNP uptake rate and extent in
FIG . 9C shows plate reader quantification at 490 nm glioblastoma , astrocytes and microglial cells . Flow cytom
excitation /520 nm emission of the FD uptake in both the etry was used to measure HALNP uptake via histogram
naked and HALNP encapsulated drug forms.
(FIG . 14A) , population wide (FIG . 14B , and per -cell fluo
FIG . 9D shows live confocal microscopy images of a rescence ( FIG . 14C ) following a 3 h and 12 h incubation
cluster of 21 MT - 1 breast cancer cells at 100x magnification 20 time in cerebellum astrocytes ( Cereb Astro ), cortical astro
with optical zoom ( Scale bars are 5 um ). The live confocal cytes (Cort Astro ), microglial ( MG ) , and three glioblastoma
microscopy images were used to confirm the intracellular (GBM ) cell lines (A172 , U251 , and U87MG) . ** p < 0.005 ,
delivery of the FD cargo .
* p <0.05 relative to both astrocytes and MG at the same time
FIG . 9E shows a representative competition assay in point; ## p <0.005 , # p <0.05 relative to the same cell type at
21MT- 1 cells .
25 the previous time point; n=4 ) . For each cell type, control
FIG . 9F shows flow cytometry assessment of per cell cells (i.e. , no HALNP ) were used to create a lower limit
uptake of fluorescent conjugated HALNPs between gating event to remove cell specific auto - fluorescence . FIG .
MCF10A and 21MT- 1 to validate uptake into the metastatic 14D shows quantitative confocal microscopy images col
cells compared to normal cells . All experiments : * P< 0.05 , lected following an analogous 3 h incubation time with
** P<0.005 , *** P<0.0001 ; n=3 .
30 HALNPs to validate the flow uptake data . The confocal
FIGS . 10A - 10B shows live confocal microscopy analysis scale bars are 50 um .
of HALNP localization in 21MT- 1 metastatic breast cancer
FIG . 15 shows CD44 protein expression analysis in six
cell line in vitro . HA - LNPs with 0.15 mass % FITC tagged cells in the GBM tumor microenvironment. Cerebellum
cholesterol in the lipid bilayer of the nanoparticles was used astrocytes (Cereb Astro ), cortical astrocytes ( Cort Astro ),
lines .

15

to track nanoparticle-endocytosis into the cell . In FIG . 10A, 35 microglial (MG) , and three glioblastoma cell lines (A172 ,

cholesterol tagged HALNPs were incubated with the
21MT- 1 cells for 5 hours and measured for co - localization
with lysosomes to determine the fraction of viable thera
peutic that escapes the nanoparticle degradation pathway. In

U251 , and U87MG) ( ** p <0.005 , * p <0.05 relative to both
Cereb Astro and Cort Astro ; n=3 ) . GAPDH was used as the
loading control.
FIG . 16 shows results of a CD44 receptor saturation assay

FIG . 10B, confocal Microscopy with a Z - axis transforma- 40 measuring the rate of per cell fluorescent HALNP uptake.
tion of 21MT- 1 cells at 100x zoom was used to validate Excess HA was used to saturate CD44 receptors, allowing
cytoplasmic delivery using the nucleus as a reference point

inside the cell (XZ plane shows the height and width of the

for the direct quantification of CD44 mediated HALNP

cell ) .

endocytosis capacity of each cell type (( ** , p < 0.005 , * p < 0.05;
n=4 ) . 3 h time point shown .

cells following transfection with miR125a - 5p in vitro . FIG .
11A shows phase contrast microscopy analysis of cellular

microscopy images with z - axis stacking to probe the
HALNP and lysosome co - localization patterns. FIG . 17B

tion ): 27 total measurements were taken at each time point
for each sample type. FIG . 11D shows a three dimensional
graphical depiction of the change in scratch width of each
sample type during the 48 h migration assay. FIG . 11E
shows one -way Anova graphical representation of the 60
scratch width during the migration assay (at time =0 h , 24 h ,
and 48 h) . Error bars shown are 95 % confidence interval.
FIG . 12 shows qRT - PCR quantification of HER2 mRNA
72 hours post transfection with miR125a - 5p . Scramble miR
was used to validate the specificity of miR125a - 5p to the 65
HER2 mRNA sequence . GAPDH gene used as a normal-

FIG . 18 shows results of a potency assay using doxoru
bicin ( DOX ) to investigate the influence of HALNP target
ing specificity and endolysosomal escape on therapeutic
efficacy. HALNP encapsulated DOX (HALNP -DOX )

FIGS . 11A - 11E show reduction of highly proliferative 45 FIGS . 17A - 17B show HALNP intracellular fate in healthy
and migrant phenotype of 21MT- 1 metastatic breast cancer glial versus GBM cells . FIG . 17A shows live cell confocal

proliferation ( transfection performed at time=0 hr. ). FIG . shows Z - axis transformation analysis with optical zoom to
11B shows an MTT assay at 72 -hours post transfection used 50 validate lysosomal evasion and subsequent achievement of
to confirm the capacity and specificity of miR125a - 5p to homogenous cytoplasmic distribution in the A172 GBM
significantly reduce proliferation. Scramble miR was used as cell . The cell nucleus was used as an internal reference point
a negative control ( ** P <0.005 , n=4 ) . FIG . 11C shows phase ( XZ and YZ planes show the cell height and width , and
contrast microscopy analysis of migration potential ( scratch height and length, respectively ). For both confocal analyses
made in confluent cell monolayer 72 h following transfec- 55 a 5 h incubation time was used and the scale bars are 10 um .

ization control ( * P <0.05 , ** P <0.005 , *** P <0.0001 ;

potency was compared between glial (cortical astrocytes
Cort Astro and microglial - MG) and GBM (A172 ) cells
following a 24 hour incubation time ( n = 3 ).
DETAILED DESCRIPTION

The ability to control the spatial distribution and temporal
release of a therapeutic remains a central challenge for
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biomedical research . Delivery via immobilization of therapeutic cargo to a solid platform demonstrates higher trans-

In some embodiments, the polyelectrolyte multilayer
comprises at least one polycationic layer. In some embodi

latable success compared to delivery using the free “ bolus ” ments, the polyelectrolyte multilayer comprises one poly
form by overcoming unfavorable burst kinetics, toxic offsite cationic layer. In some embodiments, the polyelectrolyte
effects, and / or efficacy reduction due to systemic dilution . 5 multilayer comprises at least one polycationic polymer. In
Although considerable progress has been made, there is a some embodiments, the polyelectrolyte multilayer com
polymer. In some embodiments,
lack of development of a substrate -mediated delivery system prises ofonethepolycationic
polycationic polymers are independently
capable of simultaneously controlled and truly localized each
selected from the group consisting of poly - D - lysine ( PDL) ,
delivery of therapeutics.
Accordingly, the present application provides the devel- 10 poly
-L - lysine ( PLL ), poly( diallyl dimethylammonium chlo
) ( PDAC ) , linear poly ( ethylene imine) (LPEI ) , poly
opment and optimization of a novel substrate mediated ride
-amine hydrochloride) (PAH ), chitosan ( CHI ) , a poly
therapeutic delivery system composed of hyaluronic acid (( allyl
B
amino
ester ), polyarginine, and mixtures thereof. In some
covalently functionalized liposomes (HALNPs ) embedded

embodiments , the polycationic polymer is a copolymer or

into
a polyelectrolyte multilayer ( PEM ) platform via ionic 15 block copolymer comprising two or more independently
stabilization .

Compositions
The present application provides, inter alia , a composition
comprising :
i ) one or more hyaluronic acid conjugated liposomes ; and
ii ) a polyelectrolyte multilayer.
As used herein , the term “ polyelectrolyte multilayer " (i.e. ,
PEM) refers to a multilayer formed by the deposition of one
or more polyionic polymeric thin films. In some embodiments, the polyelectrolyte multilayer comprises two or more
independently selected polyionic polymers , for example,
three or more, four or more , five or more , six or more , seven
or more , eight or more , nine or more , or ten or more
independently selected polyionic polymers . In some
embodiments, the polyelectrolyte multilayer comprises from
about 2 to about 10 polyionic polymers, for example, 2 to 10 ,
2 to 8 , 2 to 6 , 2 to 4 , 4 to 10 , 4 to 8 , 4 to 6 , 6 to 10 , 6 to 8 ,
or 8 to 10 polyionic polymers . In some embodiments, the
polyelectrolyte multilayer comprises 2 independently
selected polyionic polymers , 3 independently selected
polyionic polymers , 4 independently selected polyionic
polymers, 5 independently selected polyionic polymers, 6
independently selected polyionic polymers, 7 independently
selected polyionic polymers , 8 independently selected
polyionic polymers , 9 independently selected polyionic
polymers, 10 independently selected polyionic polymers ,
and the like.
In some embodiments, the polyelectrolyte multilayer
comprises one or more independently selected polycationic
polymers. As used herein, the term “ polycationic polymer ”
refers to a polymer having one or more positively - charged
repeat units. In some embodiments, the polycationic polymer comprises more than one positively - charged repeat unit.
In some embodiments, each repeat unit of the polycationic
polymer may be positively charged or neutral, wherein at
least one repeat unit of the polycationic polymer is positively charged. In some embodiments, each repeat unit of the
polycationic polymer is positively charged . In some embodiments, the polycationic polymer comprises at least two

positively charged repeat units and at least one neutral repeat
unit . In some embodiments , the polycationic polymer is a
block copolymer comprising at least two repeat units having

a positive charge. In some embodiments, the polycationic
polymer is a copolymer comprising at least two repeat units
having a positive charge. Example polycationic polymers

include , but are not limited to , poly - D - lysine (PDL ) , polyL - lysine (PLL ) , poly (diallyl dimethylammonium chloride)
( PDAC ), linear poly ( ethylene imine ) ( LPEI ) , poly (allylamine hydrochloride) ( PAH ), chitosan (CHI ) , a poly (ßamino ester ), polyarginine, polyethyleneimine (PEI ) , poly
( acrylic acid) ( PAA ), and poly ( 2 -dimethylaminoethyl

methacrylate) (PDMAEMA ), and mixtures thereof.

selected repeat units , wherein at least one repeat unit is
positively charged (e.g. L - lysine) . In some embodiments, at

20

25

30
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least one of the polycationic polymers is poly - L - lysine
( PLL ) .
In some embodiments, the polyelectrolyte multilayer
comprises one or more independently selected polyanionic
polymers. As used herein , the term “ polyanionic polymer ”
refers to a polymer one or more negatively -charged repeat
units . In some embodiments, the polyanionic polymer has
more than one negatively - charged repeat unit . In some
embodiments, each repeat unit of the polyanionic polymer
may be negatively charged or neutral, wherein at least two
of the repeats units are negatively charged. In some embodi
ments, the polyanionic polymer comprises at least two
negatively charged repeat units and at least one neutral
repeat unit . In some embodiments, the polyanionic polymer
is a block copolymer comprising at least two repeat units
the poly
having a negative charge. In some embodi
anionic polymer is a copolymer comprising at least two
repeat units having a negative charge. In some embodi
ments, each repeat unit of the polyanionic polymer is
negatively charged . Example polyanionic polymers include,
but are not limited to , poly ( sodium styrene sulfonate ) ( SPS ) ,
poly ( anetholesulfonic acid ) ( PAS ), poly (acrylic acid )

40 (PAA ), poly ( sodium vinylsulfonate ) (PVS ), graphene oxide
(GO ) , dextran sulfate , collagen , hyaluronic acid ( HA) , hepa
rin , and mixtures thereof.
In some embodiments, the polyelectrolyte multilayer
comprises at least one polyanionic layer. In some embodi
45 ments, the polyelectrolyte multilayer comprises one poly
anionic layer. In some embodiments, the polyelectrolyte
multilayer comprises at least one polyanionic polymer. In
some embodiments, the polyelectrolyte multilayer com
prises one polyanionic polymer. In some embodiments, each
50 of the polyanionic polymers is independently selected from
the group consisting of poly ( sodium styrene sulfonate)
( SPS ) , poly (anetholesulfonic acid ) (PAS ), poly (acrylic acid )
( PAA ), poly ( sodium vinylsulfonate ) (PVS ) , graphene oxide
(GO ) , dextran sulfate, collagen , and hyaluronic acid (HA) ,
55 and mixtures thereof. In some embodiments, the polyanionic
polymer is a copolymer or block copolymer comprising two
or more independently selected repeat units , wherein at least
one repeat unit is negatively charged (e.g. sodium styrene
sulfonate ). In some embodiments, at least one of the poly
60 anionic polymers is poly ( sodium styrene sulfonate ) ( SPS ) .
In some embodiments, the polyelectrolyte layer com
prises at least one polycationic layer and at least one
polyanionic layer. In some embodiments, the polyelectrolyte
layer comprises at least one polycationic polymer and at
65 least one polyanionic polymer. In some embodiments, the
ratio of the polycationic polymer or layer /polyanionic poly
mer or layer is from about 1 to about 2 , for example, from
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about 1 to about 2 , from about 1 to about 1.95 , from about multilayer comprises from about 5 to about 50 monolayers
1 to about 1.75 , from about 1 to about 1.5 , from about 1 to of the one or more independently selected polycationic
about 1.35 , from about 1 to about 1.25 , from about 1 to about polymers. In some embodiments , the polyelectrolyte multi
1.1 , from about 1 to about 1.05 , from about 1.05 to about 2 , layer comprises from about 5 to about 20 monolayers of the
from about 1.05 to about 1.95 , from about 1.05 to about 5 one or more independently selected polycationic polymers .
1.75 , from about 1.05 to about 1.5 , from about 1.05 to about In some embodiments, the polyelectrolyte multilayer com
1.35 , from about 1.05 to about 1.25 , from about 1.05 to prises from about 5 to about 10 monolayers of the one or
about 1.1 , from about 1.1 to about 2 , from about 1.1 to about more independently selected polycationic polymers. In some

1.95 , from about 1.1 to about 1.75 , from about 1.1 to about embodiments , the polyelectrolyte multilayer comprises from
1.5 , from about 1.1 to about 1.35 , from about 1.1 to about 10 about 10 to about 50 monolayers of the one or more

1.25 , from about 1.25 to about 2 , from about 1.25 to about independently selected polycationic polymers . In some
1.95 , from about 1.25 to about 1.75 , from about 1.25 to embodiments, the polyelectrolyte multilayer comprises from
about 1.5 , from about 1.25 to about 1.35 , from about 1.35 to about 10 to about 20 monolayers of the one or more
about 2 , from about 1.35 to about 1.95 , from about 1.35 to independently selected polycationic polymers . In some
about 1.75 , from about 1.35 to about 1.5 , from about 1.5 to 15 embodiments, the polyelectrolyte multilayer comprises from
about 2 , from about 1.5 to about 1.95 , from about 1.5 to about 20 to about 50 monolayers of the one or more
about 1.75 , from about 1.75 to about 2 , from about 1.75 to independently selected polycationic polymers.
about 1.95 , or from about 1.95 to about 2. In some embodiIn some embodiments, the polyelectrolyte multilayer
ments, the ratio of the polycationic polymer or layer/poly- comprises from about 2 to about 50 monolayers of a
2

anionic polymer or layer is from about 1 to about 1.75. In 20 polycationic polymer, for example, about 2 , about 3 , about

some embodiments, the ratio of the polycationic polymer or
layer /polyanionic polymer or layer is from about 1 to about

4 , about 5 , about 6 , about 7 , about 8 , about 9 , about 10 , about
20 , about 30 , about 40 , or about 50 of the one or more
1.5 .
independently selected cationic polymers. In some embodi
In some embodiments, at least one of the polycationic ments, the polyelectrolyte multilayer comprises from about
polymers is poly - L - lysine (PLL ) and at least one of the 25 2 to about 50 monolayers of the polycationic polymer. In
polyanionic polymers is poly (sodium styrene sulfonate) some embodiments, the polyelectrolyte multilayer com
( SPS ) . In some embodiments, the ratio of PLL/ SPS is from prises from about 2 to about 20 monolayers of the polyca
about 1 to about 2 , for example, from about 1 to about 2 , tionic polymer. In some embodiments, the polyelectrolyte
from about 1 to about 1.95 , from about 1 to about 1.75 , from multilayer comprises from about 2 to about 10 monolayers
about 1 to about 1.5 , from about 1 to about 1.35 , from about 30 of the polycationic polymer. In some embodiments, the
1 to about 1.25 , from about 1 to about 1.1 , from about 1 to polyelectrolyte multilayer comprises from about 2 to about
about 1.05 , from about 1.05 to about 2 , from about 1.05 to 5 monolayers of the polycationic polymer. In some embodi

about 1.95 , from about 1.05 to about 1.75 , from about 1.05
to about 1.5 , from about 1.05 to about 1.35 , from about 1.05

2

2

ments, the polyelectrolyte multilayer comprises from about
5 to about 50 monolayers of the polycationic polymer. In

to about 1.25 , from about 1.05 to about 1.1 , from about 1.1 35 some embodiments, the polyelectrolyte multilayer com
to about 2 , from about 1.1 to about 1.95 , from about 1.1 to
about 1.75 , from about 1.1 to about 1.5 , from about 1.1 to
about 1.35 , from about 1.1 to about 1.25 , from about 1.25 to

prises from about 5 to about 20 monolayers of the polyca
tionic polymer. In some embodiments, the polyelectrolyte
multilayer comprises from about 5 to about 10 monolayers
about 2 , from about 1.25 to about 1.95 , from about 1.25 to of the polycationic polymer. In some embodiments, the
about 1.75 , from about 1.25 to about 1.5 , from about 1.25 to 40 polyelectrolyte multilayer comprises from about 10 to about
about 1.35 , from about 1.35 to about 2 , from about 1.35 to 50 monolayers of the polycationic polymer. In some
about 1.95 , from about 1.35 to about 1.75 , from about 1.35 embodiments, the polyelectrolyte multilayer comprises from
to about 1.5 , from about 1.5 to about 2 , from about 1.5 to about 10 to about 20 monolayers of the polycationic poly
about 1.95 , from about 1.5 to about 1.75 , from about 1.75 to mer. In some embodiments, the polyelectrolyte multilayer
about 2 , from about 1.75 to about 1.95 , or from about 1.95 45 comprises from about 20 to about 50 monolayers of the
to about 2. In some embodiments , the ratio of PLL/ SPS is polycationic polymer. In some embodiments, the polyelec
from about 1 to about 1.75 . In some embodiments, the ratio trolyte multilayer comprises from about 2 to about 50
of PLL/ SPS is from about 1 to about 1.5 .
monolayers of PLL , about 2 , about 3 , about 4 , about 5 , about
In some embodiments , the polyelectrolyte multilayer 6 , about 7 , about 8 , about 9 , about 10 , about 20 , about 30 ,
comprises from about 2 to about 50 monolayers of one or 50 about 40 , or about 50 monolayers of PLL . In some embodi
2

9

more independently selected polycationic polymers, for ments, the polyelectrolyte multilayer comprises from about
example , about 2 , about 3 , about 4 , about 5 , about 6 , about 2 to about 8 monolayers of PLL . In some embodiments , the
7 , about 8 , about 9 , about 10 , about 20 , about 30 , about 40 , polyelectrolyte multilayer comprises from about 2 to about
or about 50 monolayers of the one or more independently 6 monolayers of PLL . In some embodiments, the polyelec
selected cationic polymers . In some embodiments, the poly- 55 trolyte multilayer comprises from about 3 to about 5 mono
electrolyte multilayer comprises from about 2 to about 50 layers of PLL .
monolayers of the one or more independently selected
In some embodiments, the polyelectrolyte multilayer
polycationic polymers. In some embodiments, the polyelec- comprises from about 2 to about 50 monolayers of one or
trolyte multilayer comprises from about 2 to about 20 more independently selected polyanionic polymers, for

monolayers of the one or more independently selected 60 example, about 2 , about 3 , about 4 , about 5 , about 6 , about

polycationic polymers. In some embodiments, the polyelec- 7 , about 8 , about 9 , about 10 , about 20 , about 30 , about 40 ,
trolyte multilayer comprises from about 2 to about 10 or about 50 monolayers of the one or more independently
monolayers of the one or more independently selected selected cationic polymers . In some embodiments, the poly
polycationic polymers. In some embodiments, the polyelec- electrolyte multilayer comprises from about 2 to about 50
trolyte multilayer comprises from about 2 to about 5 mono- 65 monolayers of the one or more independently selected
layers of the one or more independently selected polyca- polyanionic polymers. In some embodiments , the polyelec
tionic polymers . In some embodiments, the polyelectrolyte trolyte multilayer comprises from about 2 to about 20
9
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monolayers of the one or more independently selected
polyanionic polymers. In some embodiments, the polyelectrolyte multilayer comprises from about 2 to about 10
monolayers of the one or more independently selected
polyanionic polymers. In some embodiments , the polyelectrolyte multilayer comprises from about 2 to about 5 monolayers of the one or more independently selected polyanionic
polymers. In some embodiments, the polyelectrolyte multilayer comprises from about 5 to about 50 monolayers of the
one or more independently selected polyanionic polymers.
In some embodiments, the polyelectrolyte multilayer comprises from about 5 to about 20 monolayers of the one or
more independently selected polyanionic polymers . In some
embodiments, the polyelectrolyte multilayer comprises from
about 5 to about 10 monolayers of the one or more independently selected polyanionic polymers. In some embodiments, the polyelectrolyte multilayer comprises from about
10 to about 50 monolayers of the one or more independently
selected polyanionic polymers . In some embodiments, the
polyelectrolyte multilayer comprises from about 10 to about
20 monolayers of the one or more independently selected
polyanionic polymers. In some embodiments, the polyelectrolyte multilayer comprises from about 20 to about 50
monolayers of the one or more independently selected
polyanionic polymers.
In some embodiments , the polyelectrolyte multilayer
comprises from about 2 to about 50 monolayers of a

polycationic monolayers, two or more polycationic mono
layers, four or more polycationic monolayers , six or more
polycationic monolayers, eight or more polycationic mono
layers, or ten or more polycationic monolayers , and one or
5 more polyanionic monolayers , two or more polyanionic
monolayers, four or more polyanionic monolayers , six or
more polyanionic monolayers, eight or more polyanionic

monolayers, or ten or more polyanionic monolayers.
In some embodiments, the polyelectrolyte multilayer
10 comprises from about 1 to about 50 polycationic monolayers
and from about 1 to about 50 polyanionic monolayers, for
example, about 1 to about 50 polycationic monolayers,
about 1 to about 40 polycationic monolayers , about 1 to
about 30 polycationic monolayers , about 1 to about 20
15 polycationic monolayers, about 1 to about 10 polycationic
monolayers, about 1 to about 8 polycationic monolayers ,
about 1 to about 6 polycationic monolayers, about 1 to about

4 polycationic monolayers, about 1 to about 2 polycationic
monolayers, about 2 to about 50 polycationic monolayers,
20 about 2 to about 40 polycationic monolayers , about 2 to
nonolayers , about 2 to about 20
about 30 polycationic mo
polycationic monolayers , about 2 to about 10 polycationic
monolayers, about 2 to about 8 polycationic monolayers,
about 2 to about 6 polycationic monolayers, about 2 to about
25 4 polycationic monolayers, about 4 to about 50 polycationic
monolayers, about 4 to about 40 polycationic monolayers,
about 4 to about 30 polycationic monolayers , about 4 to
polyanionic polymer, for example , about 2 , about 3 , about 4 , about 20 polycationic monolayers , about 4 to about 10
about 5 , about 6 , about 7 , about 8 , about 9 , about 10 , about polycationic monolayers, about 4 to about 8 polycationic
20 , about 30 , about 40 , or about 50 of the one or more 30 monolayers, about 4 to about 6 polycationic monolayers,
independently selected cationic polymers. In some embodi- about 6 to about 50 polycationic monolayers , about 6 to
ments, the polyelectrolyte multilayer comprises from about about 40 polycationic monolayers , about 6 to about 30
2 to about 50 monolayers of the polyanionic polymer. In polycationic monolayers, about 6 to about 20 polycationic
>

9

some embodiments, the polyelectrolyte multilayer comprises from about 2 to about 20 monolayers of the polyanionic polymer. In some embodiments, the polyelectrolyte
multilayer comprises from about 2 to about 10 monolayers
of the polyanionic polymer. In some embodiments, the
polyelectrolyte multilayer comprises from about 2 to about
5 monolayers of the polyanionic polymer. In some embodiments , the polyelectrolyte multilayer comprises from about
5 to about 50 monolayers of the polyanionic polymer. In
some embodiments, the polyelectrolyte multilayer comprises from about 5 to about 20 monolayers of the polyanionic polymer. In some embodiments, the polyelectrolyte
multilayer comprises from about 5 to about 10 monolayers
of the polyanionic polymer. In some embodiments, the
polyelectrolyte multilayer comprises from about 10 to about
50 monolayers of the polyanionic polymer. In some embodiments, the polyelectrolyte multilayer comprises from about
10 to about 20 monolayers of the polyanionic polymer. In

monolayers, about 6 to about 10 polycationic monolayers,
35 about 6 to about 8 polycationic monolayers, about 8 to about
50 polycationic monolayers , about 8 to about 40 polyca
tionic monolayers, about 8 to about 30 polycationic mono
layers, about 8 to about 20 polycationic monolayers, about
8 to about 10 polycationic monolayers, about 10 to about 50
40 polycationic monolayers , about 10 to about 40 polycationic
monolayers, about 10 to about 30 polycationic monolayers,
about 10 to about 20 polycationic monolayers, 20 to about
50 polycationic monolayers, about 20 to about 40 polyca
tionic monolayers, about 20 to about 30 polycationic mono
45 layers, about 30 to about 50 polycationic monolayers , about
30 to about 40 polycationic monolayers, or about 30 to about
50 polycationic monolayers, and about 1 to about 50 poly
anionic monolayers, about 1 to about 40 polyanionic mono
layers, about 1 to about 30 polyanionic monolayers , about 1
50 to about 20 polyanionic monolayers, about 1 to about 10
polyanionic monolayers, about 1 to about 8 polyanionic

some embodiments, the polyelectrolyte multilayer com- monolayers , about 1 to about 6 polyanionic monolayers,
prises from about 20 to about 50 monolayers of the poly- about 1 to about 4 polyanionic monolayers, about 1 to about
anionic polymer. In some embodiments, the polyelectrolyte 2 polyanionic monolayers, about 2 to about 50 polyanionic
multilayer comprises from about 2 to about 50 monolayers 55 monolayers, about 2 to about 40 polyanionic monolayers,
of SPS , for example , about 2 , about 3 , about 4 , about 5 , about 2 to about 30 polyanionic monolayers , about 2 to
about 6 , about 7 , about 8 , about 9 , about 10 , about 20 , about about 20 polyanionic monolayers, about 2 to about 10
30 , about 40 , or about 50 monolayers of SPS . In some polyanionic monolayers, about 2 to about 8 polyanionic
embodiments, the polyelectrolyte multilayer comprises from monolayers , about 2 to about 6 polyanionic monolayers ,
about 2 to about 8 monolayers of SPS . In some embodi- 60 about 2 to about 4 polyanionic monolayers, about 4 to about
ments , the polyelectrolyte multilayer comprises from about 50 polyanionic monolayers, about 4 to about 40 polyanionic
2 to about 6 monolayers of SPS . In some embodiments, the monolayers, about 4 to about 30 polyanionic monolayers ,
polyelectrolyte multilayer comprises from about 3 to about about 4 to about 20 polyanionic monolayers , about 4 to
5 monolayers of SPS .
about 10 polyanionic monolayers, about 4 to about 8 poly
In some embodiments, the polyelectrolyte multilayer 65 anionic monolayers, about 4 to about 6 polyanionic mono
comprises one or more polycationic monolayers and one or layers, about 6 to about 50 polyanionic monolayers , about 6
more polyanionic monolayers , for example, one or more to about 40 polyanionic monolayers, about 6 to about 30
2

2

2
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polyanionic monolayers , about 6 to about 20 polyanionic
monolayers, about 6 to about 10 polyanionic monolayers,
about 6 to about 8 polyanionic monolayers, about 8 to about
50 polyanionic monolayers, about 8 to about 40 polyanionic
monolayers, about 8 to about 30 polyanionic monolayers ,
about 8 to about 20 polyanionic monolayers, about 8 to
about 10 polyanionic monolayers , about 10 to about 50
polyanionic monolayers, about 10 to about 40 polyanionic
monolayers, about 10 to about 30 polyanionic monolayers,
about 10 to about 20 polyanionic monolayers, 20 to about 50
polyanionic monolayers, about 20 to about 40 polyanionic
monolayers, about 20 to about 30 polyanionic monolayers ,
about 30 to about 50 polyanionic monolayers , about 30 to
about 40 polyanionic monolayers, or about 30 to about 50
polyanionic monolayers, In some embodiments, the polyelectrolyte multilayer comprises about 5 polycationic mono
layers and about 4 polyanionic monolayers. In some
embodiments, the polyelectrolyte multilayer comprises
about 5 monolayers of PLL and about 4 monolayers of SPS .
In some embodiments, the polyelectrolyte multilayer is
prepared using sequential deposition of two or more
polyionic polymers . In some embodiments, the polyelectrolyte multilayer is prepared using sequential deposition of at
least one polycationic polymer and at least one polyanionic

polymer. In some embodiments, the polyelectrolyte multilayer is prepared using sequential deposition of one polycationic polymer and one polyanionic polymer.
Another component of the composition includes
hyaluronic acid (HA ) covalently bonded to the liposome . In
some embodiments, the hyaluronic acid is conjugated on the
surface of the liposome . In some embodiments , the
hyaluronic acid is conjugated on the lipid head group of the
liposome . In some embo
its, the liposome comprises a
hydrophilic core . In some embodiments , the liposome comprises a lipid component selected from the group consisting
of 1,2 -dioleoyl - sn -glycero - 3 -phoshocholine ( DOPC ) , 1,2dimyristoyl - sn -glycero - 3 - phosphocholine ( DMPC ) , 1,2 -distearoyl-sn - glycero - 3 -phosphocholine, ( DSPC ) , 1,2 -dilauroyl - sn - glycero - 3 -phosphocholine (DLPC ) , dipalmitoylphosphatidylcholine ( DPPC ) , and L a -phosphatidylcholine
( PC ) . In some embodiments, the liposome comprises 1,2dipalmitoyl - sn - glycero - 3 - phopshoethanolamine (DPPE )

embodiments, at least one of the therapeutic agents is a
chemotherapeutic agent. In some embodiments, at least one
of the therapeutic agents is a silencing RNA .
Example anti- angiogenic agents include , but are not lim
5 ited to a VEGF inhibitor, bevacizumab , thalidomide , itra

conazole , carboxyamidotriazole, TNP - 470 , IFN - A , IL - 12 ,

platelet factor - 4 , suramin , thrombospondin , angiostatin ,
endostatin , 2 -methoxyestradiol, tecogalan, prolactin , lino

mide, ranibizumab , sorafenib , sunitinib , pazopanib , and
10 everolimus
.
Example gene therapy agents include , but are not limited
to DNA - based therapy agents, somatic cell gene therapy

( SCGT ) agents , and germline gene therapy (GTGT) agents .
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Example steroids include , but are not limited to , corti
costeroids such as cortisone , dexamethasone, hydrocorti

sone, methylprednisolone, prednisolone, and prednisone.
Example immunosuppressants include , but are not limited
to , azathioprine , chlorambucil, cyclophosphamide,
cyclosporine, daclizumab , infliximab , methotrexate, and tac
rolimus .
Example anti -microbial agents include, but are not limited
to , aminoglycosides ( e.g. , gentamicin, neomycin, and strep
tomycin ), penicillins ( e.g. , amoxicillin and ampicillin ) , and
macrolides (e.g. , erythromycin ).
Example anti- fungal agents include , but are not limited to ,
polyene anti -fungal agents (e.g. , amphotericin B and candi
cidin) , imidazole anti- fungal agents (e.g. , bifonazole, clotri
mazole , and econazole ) , triazole anti -fungal agents ( e.g. ,
albaconazole, efinaconazole , and fluconazole ), thiazole anti
fungal agents ( e.g. , abafungin ), allylamine anti - fungal
agents ( e.g. , amorolfin , butenafine, and naftifine ), echi
nocandins ( e.g. , anidulafungin and caspofungin ).
Example anti - inflammatory agents include, but are not
limited to , aspirin, choline salicylates, celecoxib , diclofenac
potassium , diclofenac sodium , diclofenac sodium with
misoprostol, diflunisal, etodolac, fenoprofen , flurbiprofen ,
ibuprofen, ketoprofen, meclofenamate sodium , mefenamic
acid, nabumetone, naproxen , naproxen sodium , oxaprozin ,
piroxican, rofecoxib , salsalate , sodium salicylate , sulindac ,
tolmetin sodium , and valdecoxib .
Example chemotherapeutics include, but are not limited

and cholesterol (CHOL ) . In some embodiments, the lipo- to , an alkylating agent ( e.g. , busulfan , carmustine ), an anti
some comprises 1,2 -dipalmitoyl-sn - glycero -3 -phopshoetha- metabolite (e.g. , 5 - fluoro uracil, gemcitabine, methotrexate ),
nolamine ( DPPE ) and cholesterol (CHOL ) , and one or more 45 an anti - tumor antibiotic (e.g. dactinomycin , doxorubicin ,
hyaluronic acids . In some embodiments, the one or more epirubicin ), a topoisomerase inhibitor ( e.g. topotecan, irino
hyaluronic acids are coated on the surface of the DPPE/ tecan ), a mitotic inhibitor (e.g. , paclitaxel, ixabepilone,
CHOL liposome . In some embodiments, a hyaluronic acid vinblastine, estramustine ), a plant alkaloid or a microtubule
conjugated liposome provided herein is prepared according inhibitor ( e.g. docetaxel , irinotecan , etoposide ), a DNA

50 linking agent ( e.g., carboplatin , cisplatin , oxaliplatin ), an
In some embodiments, the liposome further comprises immunotherapeutic agent (e.g , rituximab , alemtuzumab ,
one or more therapeutic agents . In some embodiments, the lenalidomide) , and a differentiating agent (e.g. tretinoin ,
one or more therapeutic agents are localized in the hydro- bexarotene ), cisplatin, doxorubicin , etoposide , irinotecan ,
philic core or the hydrophobic bilayer of the liposome . In topotecan, paclitaxel, docetaxel , tamoxifen , 5 - fluorouracil,
some embodiments, the one or more therapeutic agents are 55 methotrexate, temozolomide, cyclophosphamide, gefitinib ,
localized in the hydrophilic core of the liposome . In some erlotinib hydrochloride, imatinib mesylate , cytarabine,
embodiments, one or more therapeutic agents localized in gemcitabine, uracil mustard, chlormethine, ifosfamide,
the hydrophobic core of the liposome . In some embodi- chlorambucil, pipobroman , triethylenemelamine, busulfan ,
ments, the one or more therapeutic agents are each inde- carmustine, lomustine , streptozocin , dacarbazine, floxuri
pendently selected from the group consisting of aa chemo- 60 dine , 6 -mercaptopurine, 6 - thioguanine, fludarabine phos
therapeutic agent, a silencing RNA , a steroid , an phate, oxaliplatin , pentostatin, vinblastine, vincristine, vin
immunosuppressant, an anti-microbial agent, an anti- fungal desine , bleomycin , dactinomycin , daunorubicin , epirubicin ,
agent, an anti -inflammatory agent, a gene therapy agent, an idarubicin , deoxycoformycin , mitomycin - C , L -asparagi
anti - angiogenic agent, a stem cell (e.g. , for bone marrow nase , teniposide, testolactone , estramustine, carboplatin ,
transplantation ), and a CRISPR /Cas9 component. In some 65 hydroxyurea , amsacrine, procarbazine, mitotane , mitoxan
embodiments, at least one of the therapeutic agents is a trone , vinorelbine, anastrazole, letrozole, capecitabine, ral
chemotherapeutic agent or a silencing RNA . In some oxifene, xeloda , vinorelbine, cetuximab , N ,N'N '-triethyl

to a procedure described herein .
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enethiophosphoramide,

altretamine,

20

trastuzumab ,

fulvestrant, exemestane, and any combination thereof.
Example silencing RNAs include, but are not limited to ,
small interfering RNA ( siRNA ) and microRNA (miRNA ),
and short hairpin RNA ( shRNA ).
Example CRISPR / Cas9 components include , but are not
limited Cre recombinase , TALE , and Cas9 based transcription factors (e.g. to promote genome modification ). Additional examples of CRISPR /Cas9 component may be found,
e.g. , at Zuris et al . , Nature Biotechnology, 2015 , 33 , 73-80 .
In some embodiments , the chemotherapeutic agent is
selected from the group consisting of an alkylating agent, an
anti-metabolite, an anti -tumor antibiotic, a topoisomerase
inhibitor, a mitotic inhibitor, a plant alkaloid , a microtubule
inhibitor, a DNA linking agent, an immunotherapeutic agent,
and a differentiating agent. In some embodiments, the chemotherapeutic agent is an anti - tumor antibiotic. In some
embodiments, the chemotherapeutic agent is doxorubicin .
In some embodiments , the liposome further comprises a
fluorescently tagged lipid , for example, a fluorescently
tagged cholesterol, a fluorescently tagged phosphatidylcholine , a fluorescently tagged sphingolipid , a fluorescently
tagged phospholipid , a fluorescently tagged oxidized lipid ,
and aa fluorescently tagged sterol. In some embodiments, the
fluorescently tagged lipid is a fluorescently tagged cholesterol .
In some embodiments , the liposome further comprises a
targeting moiety . Example targeting moieties include, but
are not limited to HER2 , ER , and PR , for example, for the
treatment of breast cancer; CD44 , for example , for the
treatment of cancer; and IL - 13 , for example, for the treatment of glioblastoma . In some embodiments, the targeting
moiety is conjugated to the hyaluronic acid . In some
embodiments, the targeting moiety is selected from the
group consisting of an antibody, a small molecule , a polypeptide, an aptamer, a folate, a transferrin , a glycoprotein , an
integrin , and a carbohydrate.
In some embodiments, the one or more hyaluronic acid

consisting of poly - D - lysine ( PDL ) , poly - L - lysine ( PLL ) ,

5
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conjugated liposomes is deposited onto the polyelectrolyte
multilayer.
40
In some embodiments, a composition provided herein

further comprises an additional polyelectrolyte multilayer
( i.e. , a capping layer or a capping multilayer ). In some
embodiments , the additional polyelectrolyte multilayer
forms a capping layer upon the one or more hyaluronic acid
conjugated liposome . In some embodiments, the additional
polyelectrolyte multilayer is deposited onto the one or more
hyaluronic acid conjugated liposomes , wherein the one or
more hyaluronic acid conjugated liposomes are located in
between the polyelectrolyte multilayer and the additional
polyelectrolyte multilayer ( i.e. , the capping layer ).
In some embodiments, the polyelectrolyte multilayer
comprises two or more independently selected polyionic
polymers, for example, 2 independently selected polyionic
polymers, 3 independently selected polyionic polymers, 4
independently selected polyionic polymers, 5 independently
selected polyionic polymers , 6 independently selected
polyionic polymers, 7 independently selected polyionic
polymers, 8 independently selected polyionic polymers, 9
independently selected polyionic polymers , 10 independently selected polyionic polymers, and the like .
In some embodiments, the additional polyelectrolyte multilayer comprises one or more independently selected polycationic polymers . In some embodiments, the additional
polyelectrolyte multilayer comprises at least one polycationic polymer. In some embodiments, each of the polycationic polymers is independently selected from the group

45

50

55
60
65

poly (diallyl dimethylammonium chloride) (PDAC ), linear
poly ( ethylene imine) ( LPEI ) , poly ( allyl - amine hydrochlo
ride ) (PAH ), chitosan (CHI ) , a poly ( ß - amino ester ), and
polyarginine. In some embodiments , the additional poly
electrolyte multilayer comprises one polycationic polymer.
In some embodiments, the additional polyelectrolyte mul
tilayer comprises one or more independently selected poly
anionic polymers . In some embodiments, the additional
polyelectrolyte multilayer comprises at least one polyan
ionic polymer. In some embodiments, each of the polyan
ionic polymers is independently selected from the group
consisting of poly ( sodium styrene sulfonate) ( SPS ) , poly
( anetholesulfonic acid ) (PAS ), polyacrylic acid ) ( PAA ),
poly ( sodium vinylsulfonate) ( PVS ), graphene oxide (GO ),
dextran sulfate , collagen , and hyaluronic acid (HA ).In some
embodiments, each the additional polyelectrolyte multilayer
comprises one polyanionic polymer.
In some embodiments, at least one of the polycationic
polymers is poly - L -lysine (PLL ) and at least one of the
polyanionic polymers is poly ( sodium styrene sulfonate )
( SPS ) .
In some embodiments, the additional polyelectrolyte mul
tilayer comprises from about 2 to about 10 monolayers of
one or more independently selected polycationic polymers ,
for example, about 2 , about 3 , about 4 , about 5 , about 6 ,
about 7 , about 8 , about 9 , or about 10 monolayers one or
more independently selected cationic polymers. In some
embodiments, the additional polyelectrolyte multilayer
comprises from about 2 to about 8 monolayers of one or
more independently selected polycationic polymers . In some
embodiments, the additional polyelectrolyte multilayer
comprises from about 2 to about 6 monolayers of one or
more independently selected polycationic polymers . In some
embodiments, the additional polyelectrolyte multilayer
comprises from about 3 to about 5 monolayers of one or
more independently selected polycationic polymers.
In some embodiments , the additional polyelectrolyte mul
tilayer comprises from about 2 to about 10 monolayers of a
polycationic polymer, for example , about 2 , about 3 , about
4 , about 5 , about 6 , about 7 , about 8 , about 9 , or about 10
monolayers one or more independently selected cationic
polymers. In some embodiments, the additional polyelec
trolyte multilayer comprises from about 2 to about 8 mono
layers of a polycationic polymer. In some embodiments, the
additional polyelectrolyte multilayer comprises from about
2 to about 6 monolayers of a polycationic polymer. In some
embodiments , the additional polyelectrolyte multilayer
comprises from about 3 to about 5 monolayers of a poly
cationic polymer.
In some embodiments, the additional polyelectrolyte mul
tilayer comprises from about 2 to about 10 monolayers of
PLL , about 2 , about 3 , about 4 , about 5 , about 6 , about 7 ,
about 8 , about 9 , or about 10 monolayers of PLL . In some
embodiments, the additional polyelectrolyte multilayer
comprises from about 2 to about 8 monolayers of PLL . In
some embodiments, the additional polyelectrolyte multi
layer comprises from about 2 to about 6 monolayers of PLL .
In some embodiments, the additional polyelectrolyte multi
layer comprises from about 3 to about 5 monolayers of PLL .
In some embodiments, the additional polyelectrolyte mul
tilayer comprises from about 2 to about 10 monolayers of
one or more independently selected polyanionic polymers,
for example, about 2 , about 3 , about 4 , about 5 , about 6 ,
about 7 , about 8 , about 9 , or about 10 monolayers one or
more independently selected cationic polymers. In some
embodiments , the additional polyelectrolyte multilayer
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comprises from about 2 to about 8 monolayers of one or

implant, a metal rod, a cardiac pace maker, a surgical staple,

more independently selected polyanionic polymers. In some a surgical suture, a needle , a balloon , a bandage, a wound
embodiments, the additional polyelectrolyte multilayer graft, and a cartilage substitute. In some embodiments, a
comprises from about 2 to about 6 monolayers of one or composition provided herein is coated onto at least one
more independently selected polyanionic polymers. In some 5 surface of a device . In some embodiments, a composition
embodiments, the additional polyelectrolyte multilayer provided herein is coated onto at least one surface of a
comprises from about 3 to about 5 monolayers of one or medical device.
more independently selected polyanionic polymers.
In some embodiments:
In some embodiments, the additional polyelectrolyte mul
the one or more hyaluronic acid conjugated liposomes
tilayer comprises
from, forabout
2 to, about
monolayers
comprise one or more therapeutic agents; and
polyanionic
polymer
example
about 10
2 , about
3 , aboutof4a, 10 further
the
polyelectrolyte
multilayer comprises two more inde
about 5 , about 6 , about 7 , about 8 , about 9 , or about 10 pendently selected polyionic
polymers .
monolayers one or more independently selected cationic
In
some
embodiments
:
polymers. In some embodiments, the additional polyelec
the one or more hyaluronic acid conjugated liposomes
trolyte multilayer comprises from about 2 to about 8 mono- 15 further
comprise one or more therapeutic agents; and
layers of a polyanionic polymer. In some embodiments, the
additional polyelectrolyte multilayer comprises from about
the polyelectrolyte multilayer comprises one or more
2 to about 6 monolayers of a polyanionic polymer. In some independently selected polycationic polymers.
embodiments, the additional polyelectrolyte multilayer
In some embodiments :
comprises from about 3 to about 5 monolayers of a poly- 20 the one or more hyaluronic acid conjugated liposomes
anionic polymer.
further comprise one or more therapeutic agents ;
In some embodiments, the additional polyelectrolyte multhe polyelectrolyte multilayer comprises one or more
tilayer comprises from about 2 to about 10 monolayers of independently selected polycationic polymers; and
SPS , for example, about 2 , about 3 , about 4 , about 5 , about
each of the polycationic polymers is independently
6 , about 7 , about 8 , about 9 , or about 10 monolayers of SPS . 25 selected from the group consisting of poly - D - lysine ( PDL) ,
In some embodiments, the additional polyelectrolyte multi poly - L - lysine ( PLL ) , poly ( diallyl dimethylammonium chlo
layer comprises from about 2 to about 8 monolayers of SPS . ride) (PDAC ), linear polyethylene imine) ( LPEI ) , poly
In some embodiments , the additional polyelectrolyte multi ( allyl - amine hydrochloride ) (PAH ), chitosan ( CHI ) , a poly
layer comprises from about 2 to about 6 monolayers of SPS . (ß - amino ester ), and polyarginine.
In some embodiments, the additional polyelectrolyte multi- 30 In some embodiments:
layer comprises from about 3 to about 5 monolayers of SPS .
the one or more hyaluronic acid conjugated liposomes
In some embodiments, the additional polyelectrolyte mul
comprise one or more therapeutic agents ;
tilayer is prepared using sequential deposition of two or further
the
polyelectrolyte
multilayer comprises a polycationic
more polyionic polymers . In some embodiments, the addi
tional
polyelectrolyte multilayer is prepared using sequential 35 polymer
selected
from
the
consisting
poly - D -lysine
( PDL ) , poly - L - lysine ( PLLgroup
), poly
( diallyl ofdimethylammo
deposition of at least one polycationic polymer and at least nium
chloride) (PDAC ) , linear poly ( ethylene imine) (LPEI ) ,
one polyanionic polymer. In some embodiments, the addi
tional polyelectrolyte multilayer is prepared using sequential poly ( allyl - amine hydrochloride) ( PAH ), chitosan ( CHI ) , a
deposition of one polycationic polymer and one polyanionic poly ( ß - amino ester) , and polyarginine.
40
polymer.
In some embodiments:
In some embodiments, the additional polyelectrolyte multhe one or more hyaluronic acid conjugated liposomes
tilayer is deposited onto the one or more hyaluronic acid further comprise one or more therapeutic agents ;
conjugated liposomes . In some embodiments , the additional
the polyelectrolyte multilayer comprises one or more
polyelectrolyte multilayer forms a capping layer upon the independently selected polycationic polymers; and the com
one or more hyaluronic acid conjugated liposome . In some 45 position further comprises a substrate.
9

embodiments, the additional polyelectrolyte multilayer is
deposited onto the one or more hyaluronic acid conjugated

In some embodiments :
the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ;

liposomes , wherein the one or more hyaluronic acid conjugated liposomes are located in between the polyelectrolyte
the polyelectrolyte multilayer comprises one or more
multilayer and the additional polyelectrolyte multilayer (i.e. , 50 independently selected polycationic polymers;
the capping layer).
each of the polycationic polymers is independently
In some embodiments:
selected from the group consisting of poly - D - lysine ( PDL) ,
i ) one or more hyaluronic acid conjugated liposomes are poly - L - lysine ( PLL ) , poly ( diallyl dimethylammonium chlo
deposited onto the polyelectrolyte multilayer , and
ride) ( PDAC ) , linear poly (ethylene imine) (LPEI ) , poly
ii ) the additional polyelectrolyte multilayer is subse- 55 ( allyl - amine hydrochloride) ( PAH ), chitosan ( CHI ) , a poly
quently deposited onto the one or more hyaluronic acid ( B -amino ester ), and polyarginine; and the composition
conjugated liposomes .
further comprises a substrate.
In some embodiments , a composition provided herein is
In some embodiments :
deposited onto a substrate. In some embodiments, the comthe one or more hyaluronic acid conjugated liposomes
position is coated onto at least one surface the substrate. In 60 further comprise one or more therapeutic agents;
some embodiments , the substrate is selected from the group
the polyelectrolyte multilayer comprises a polycationic
consisting of a medical device , a tablet,a capsule, a bandage, polymer selected from the group consisting of poly - D - lysine
a gel , a nanoparticle , an oxygen plasma treated surface , a ( PDL ) , poly - L - lysine (PLL ), poly (diallyl dimethylammo

sterile glass slide, a sterile glass plate , a tissue culture plate , nium chloride) (PDAC ) , linear poly ( ethylene imine) (LPEI ) ,
and a cell culture plate . In some embodiments, the medical 65 poly ( allyl - amine hydrochloride) ( PAH ), chitosan (CHI ) , a
device is selected from the group consisting of a stent, a

catheter, a syringe, a needle , a microneedle, a medical

poly ( ß - amino ester ), and polyarginine; and the composition
further comprises a substrate .
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the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ; and
the polyelectrolyte multilayer comprises one or more
independently selected polyanionic polymers .
In some embodiments :
the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ;
the polyelectrolyte multilayer comprises one or more
independently selected polanionic polymers; and
each of the polyanionic polymers is independently

( acrylic acid ) (PAA ), poly (sodium vinylsulfonate ) ( PVS ) ,
graphene oxide ( GO ) , dextran sulfate, collagen , and

sulfonate) ( SPS ) , poly ( anetholesulfonic acid) ( PAS ), poly

In some embodiments:

5

10

selected from the group consisting of poly( sodium styrene

sulfonate) ( SPS ) , poly (anetholesulfonic acid) (PAS ), poly
( acrylic acid) (PAA ), poly ( sodium vinylsulfonate ) ( PVS ) ,
graphene oxide (GO), dextran sulfate, collagen, and is
hyaluronic acid ( HA) .
In some embodiments:
the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ;
the polyelectrolyte multilayer comprises a polyanionic 20
polymer selected from the group consisting of poly ( sodium
styrene sulfonate) ( SPS ) , poly (anetholesulfonic acid) (PAS ),
poly (acrylic acid) ( PAA ), poly (sodium vinylsulfonate )

(PVS ), graphene oxide (GO ), dextran sulfate , collagen , and

hyaluronic acid (HA ).

25

In some embodiments:

the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ;

the polyelectrolyte multilayer comprises one or more
independently selected polyanionic polymers, and the com- 30

position further comprises a substrate .
In some embodiments:
the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ;

the polyelectrolyte multilayer comprises one or more 35
independently selected polanionic polymers;
each of the polyanionic polymers is independently
selected from the group consisting of poly ( sodium styrene
sulfonate ) ( SPS ) , poly ( anetholesulfonic acid) ( PAS ), poly
( acrylic acid) (PAA ), poly ( sodium vinylsulfonate ) ( PVS ) , 40
graphene oxide (GO ) , dextran sulfate, collagen, and
hyaluronic acid (HA) ; and the composition further com-

prises a substrate.
In some embodiments:
the one or more hyaluronic acid conjugated liposomes 45
further comprise one or more therapeutic agents ;
the polyelectrolyte multilayer comprises a polyanionic
polymer selected from the group consisting of poly ( sodium

styrene sulfonate ) ( SPS ) , poly (anetholesulfonic acid) (PAS ),
polyacrylic acid ) ( PAA ), poly (sodium vinylsulfonate ) 50
(PVS ), graphene oxide (GO ) , dextran sulfate, collagen , and

hyaluronic acid (HA) ; and the composition further comprises a substrate .
In some embodiments :

hyaluronic acid ( HA) .
In some embodiments :
the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ;
the polyelectrolyte multilayer comprises one polycationic
polymer and one polyanionic polymer;
wherein the polycationic polymer is selected from the
group consisting of poly - D - lysine ( PDL ) , poly - L - lysine
(PLL ) , poly (diallyl dimethylammonium chloride ) ( PDAC ) ,
linear polyethylene imine ) ( LPEI ) , poly ( allyl - amine hydro
chloride) (PAH; and), chitosan (CHI) , a poly(ß -amino ester), and
polyarginine
the polyanionic polymer is selected from the group con
sisting of poly ( sodium styrene sulfonate ) ( SPS ) , poly (anet
holesulfonic acid) ( PAS ), poly ( acrylic acid ) ( PAA ), poly
(sodium vinylsulfonate) ( PVS ), graphene oxide (GO ),
dextran sulfate , collagen, and hyaluronic acid ( HA) .
In some embodiments:
the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents ;
the polyelectrolyte multilayer comprises one or more
independently selected polycationic polymers and one or
more independently selected polyanionic polymers;
wherein each of the polycationic polymers is indepen
dently selected from the group consisting of poly - D - lysine
( PDL ) , poly - L - lysine ( PLL ), poly (diallyl dimethylammo
nium chloride ) (PDAC ), linear polyethylene imine ) ( LPEI ) ,
poly ( allyl - amine hydrochloride) ( PAH ), chitosan (CHI ) , a
poly ( ß - amino ester) , and polyarginine;
each of the polyanionic polymers is independently
selected from the group consisting of poly ( sodium styrene
sulfonate ) ( SPS ) , poly ( anetholesulfonic acid) ( PAS ), poly
( acrylic acid ) (PAA ), poly ( sodium vinylsulfonate ) ( PVS ) ,
graphene oxide (GO ) , dextran sulfate , collagen, and
hyaluronic acid ( HA) ; and the composition further com
prises a substrate.
In some embodiments :
the one or more hyaluronic acid conjugated liposomes
further comprise one or more therapeutic agents;
the polyelectrolyte multilayer comprises one polycationic
polymer and one polyanionic polymer;
wherein the polycationic polymer is selected from the
group consisting of poly - D -lysine ( PDL ) , poly - L - lysine
( PLL ) , poly ( diallyl dimethylammonium chloride) ( PDAC ),
linear polyethylene imine ) ( LPEI ) , poly (allyl-amine hydro
chloride ) ( PAH ), chitosan ( CHI ) , a poly ( B -amino ester ), and
polyarginine;
the polyanionic polymer is selected from the group con
sisting of poly ( sodium styrene sulfonate ) ( SPS ) , poly (anet
holesulfonic acid ) (PAS ), polyacrylic acid ) ( PAA ), poly
( sodium vinylsulfonate ) ( PVS ), graphene oxide (GO ) ,
dextran sulfate, collagen , and hyaluronic acid ( HA) ; and the
composition further comprises a substrate .

the one or more hyaluronic acid conjugated liposomes 55
further comprise one or more therapeutic agents ;
the polyelectrolyte multilayer comprises one or more
independently selected polycationic polymers and one or
In some embodiments :
the one or more hyaluronic acid conjugated liposomes
more independently selected polyanionic polymers;
wherein each of the polycationic polymers is indepen- 60 further comprise one or more therapeutic agents;
dently selected from the group consisting of poly - D - lysine
the polyelectrolyte multilayer comprises one or more
( PDL ) , poly - L - lysine ( PLL ) , poly ( diallyl dimethylammo- independently selected polycationic polymers and one or
nium chloride ) (PDAC ), linear polyethylene imine) ( LPEI ) , more independently selected polyanionic polymers;
poly (allyl -amine hydrochloride ) (PAH ), chitosan ( CHI ) , a
wherein each of the polycationic polymers is indepen
65 dently selected from the group consisting of poly - D - lysine
poly ( ß - amino ester ), and polyarginine; and
each of the polyanionic polymers is independently (PDL ) , poly - L - lysine ( PLL ) , poly (diallyl dimethylammo
selected from the group consisting of poly ( sodium styrene nium chloride ) (PDAC ) , linear poly (ethylene imine) (LPEI ) ,
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poly (allyl - amine hydrochloride) ( PAH ), chitosan (CHI ) , a
poly (ß -amino ester ), and polyarginine;
each of the polyanionic polymers is independently
selected from the group consisting of poly ( sodium styrene

more independently selected polyanionic polymers
wherein at least one of the polycationic polymers is poly
L - lysine ( PLL ) and at least one of the polyanionic polymers
is poly ( sodium styrene sulfonate ) ( SPS ) ;
sulfonate ) ( SPS ) , poly (anetholesulfonic acid ) (PAS ), poly 5 and the composition further comprises a substrate.
( acrylic acid) (PAA ), poly ( sodium vinylsulfonate ) ( PVS ) , Preparation of Compositions
graphene oxide (GO ) , dextran sulfate, collagen, and
The present application further provides methods of pre
hyaluronic acid ( HA) ;
paring
compositions provided herein . In some embodi
wherein at least one of the polycationic polymers is ments , the
the
method comprises:
poly - L - lysine (PLL ) and at least one of the polyanionic 10 i ) sequentially
depositing two or more polyionic polymers
polymers is poly ( sodium styrene sulfonate ) ( SPS ) ; and
to
form
the
polyelectrolyte
multilayer, and
the composition further comprises a substrate .
ii
)
depositing
the
one
or
more
hyaluronic acid conjugated
In some embodiments:
liposomes
onto
the
polyelectrolyte
multilayer. In some
the one or more hyaluronic acid conjugated liposomes
embodiments
,
the
sequential
deposition
of step i ) is per
15
further comprise one or more therapeutic agents ;
the polyelectrolyte multilayer comprises one polycationic formed in solution . In some embodiments , the sequential
deposition of step i ) is performed in an aqueous solution . In
polymer and one polyanionic polymer ;
wherein the polycationic polymer is selected from the some embodiments, the sequential deposition of step i ) is
group consisting of poly - D -lysine ( PDL ) , poly - L - lysine performed in deionized water.
( PLL ) , poly (diallyl dimethylammonium chloride) ( PDAC ) , 20 In some embodiments , the deposition of step ii ) is per
linear polyethylene imine ) ( LPEI ) , poly (allyl - amine hydro- formed in solution . In some embodiments, the deposition of
chloride) (PAH ), chitosan (CHI ) , a poly ( ß - amino ester ), and step ii ) is performed in a buffered aqueous solution . In some
polyarginine;
embodiments, the pH of the buffered aqueous solution is
the polyanionic polymer is selected from the group con- from about 7.5 to about 9. In some embodiments , the
sisting of poly ( sodium styrene sulfonate ) ( SPS ) , poly (anet- 25 buffered aqueous solution further comprises a carboxyl
holesulfonic acid) ( PAS ), poly ( acrylic acid) ( PAA ), poly amine coupling agent. In some embodiments, the carboxyl
( sodium vinylsulfonate ) ( PVS ) , graphene oxide (GO ) , amine coupling agent is selected from the group consisting
dextran sulfate, collagen , and hyaluronic acid ( HA) ; and the of N ,N - dicyclohexylcarbodiimide (DCC ), N , N -diisopropy
lcarbodiimide ( DIC ) , and 1 -ethyl-3- (3 -dimethylaminopro
composition further comprises a substrate.
In some embodiments:
30 pyl )carbodiimide (EDAC ) . In some embodiments, the car
the one or more hyaluronic acid conjugated liposomes boxyl- amine coupling agent is 1 - ethyl-3-(3
dimethylaminopropyl ) carbodiimide (EDAC ).
further comprise one or more therapeutic agents ;
the polyelectrolyte multilayer comprises one polycationic
In some embodi nts , at least one of the polyionic
polymer and one polyanionic polymer ;
polymers is a polycationic polymer provided herein and at
wherein the polycationic polymer is selected from the 35 least one of the polyionic polymers is polyanionic polymer
group consisting of poly - D - lysine ( PDL ) , poly - L - lysine provided herein . In some embodiments, at least one of the
(PLL ), poly (diallyl dimethylammonium chloride) (PDAC ), polycationic polymers is poly - L - lysine (PLL ) and at least
linear poly ( ethylene imine) ( LPEI ) , poly (allyl- amine hydro- one of the polyanionic polymers is poly ( sodium styrene
chloride ) (PAH ), chitosan (CHI ) , a poly ( ß -amino ester ), and sulfonate) ( SPS ) .
40
polyarginine;
In some embodiments, step ii ) comprises contacting the
the polyanionic polymer is selected from the group con- one or more hyaluronic acid conjugated liposomes with the
or

2

2

sisting of poly ( sodium styrene sulfonate) ( SPS ) , poly (anet- polyelectrolyte multilayer at about room temperature.
holesulfonic acid) ( PAS ), poly (acrylic acid) ( PAA ), poly
The present application further provides a method of
( sodium vinylsulfonate ) (PVS ), graphene oxide ( GO ) , preparing a composition provided herein , the method com
dextran sulfate, collagen , and hyaluronic acid (HA) ;
45 prising:
the additional polyelectrolyte multilayer comprises one or
i ) sequentially depositing two or more polyionic polymers
more independently selected polycationic polymers and one to form the polyelectrolyte multilayer;
or more independently selected polyanionic polymers;
ii ) depositing the one or more hyaluronic acid conjugated
and the composition further comprises a substrate.
liposomes onto the polyelectrolyte multilayer, and
50
iii ) depositing the additional polyelectrolyte multilayer
In some embodiments :
the one or more hyaluronic acid conjugated liposomes onto the one or more hyaluronic acid conjugated liposomes .
In some embodiments, the sequential deposition of steps
further comprise one or more therapeutic agents ;
the polyelectrolyte multilayer comprises one polycationic i ) is performed in solution . In some embodiments , the
polymer and one polyanionic polymer ;
sequential deposition of step i ) is performed in an aqueous
wherein the polycationic polymer is selected from the 55 solution . In some embodiments, the sequential deposition of
group consisting of poly - D - lysine ( PDL ) , poly - L - lysine step i ) is performed in deionized water .
( PLL ) , poly (diallyl dimethylammonium chloride) ( PDAC ) ,
In some embodiments , the deposition of step ii ) is per
linear polyethylene imine ) ( LPEI ) , poly (allyl- amine hydro- formed in solution . In some embodiments, the deposition of
chloride) (PAH ), chitosan (CHI ) , a poly ( ß - amino ester ), and step ii ) is performed in aa buffered aqueous solution . In some
polyarginine;
60 embodiments, the pH of the buffered aqueous solution is
the polyanionic polymer is selected from the group con- from about 7.5 to about 9. In some embodiments, the
sisting of poly ( sodium styrene sulfonate ) ( SPS ) , poly (anet- buffered aqueous solution further comprises a carboxyl
holesulfonic acid ) (PAS ), poly (acrylic acid ) (PAA ), poly amine coupling agent. In some embodiments, the carboxyl
( sodium vinylsulfonate ) ( PVS ) , graphene oxide (GO ) , amine coupling agent is selected from the group consisting
dextran sulfate, collagen, and hyaluronic acid ( HA ) ;
65 of N , N - dicyclohexylcarbodiimide (DCC ), N ,N -diisopropy
the additional polyelectrolyte multilayer comprises one or lcarbodiimide (DIC ), and 1 -ethyl- 3- (3 -dimethylaminopro

more independently selected polycationic polymers and one

pyl )carbodiimide (EDAC ) . In some embodiments, the car
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boxyl-amine coupling agent is 1 -ethyl- 3- (3In some embodiments, the leukemia is selected from the
dimethylaminopropyl )carbodiimide (EDAC ).
group consisting of acute myeloid leukemia (AML ) , chronic
In some embodiments, step ii ) comprises contacting the lymphocytic leukemia (CLL ) , chronic myelogenous leuke
one or more hyaluronic acid conjugated liposomes with the mia ( CML ) , multiple myeloma, hairy cell leukemia , T -cell
5 actute lymphoblasic leukemia ( T - ALL ), and large granular
polyelectrolyte multilayer at about room temperature .
leukemia .
In some embodiments, the contacting is performed from lymphocytic
In some embodiments, the lymphoma is selected from the
about 1 to about 10 hours, for example, from about 1 to group
consisting of small lymphocytic lymphoma, cutane
about 10 hours , from about 1 to about 8 hours , from about ous T - cell
lymphoma, Burkitt's lymphoma, peripheral T - cell
4 hours , from about
11 toto about
about62hours
hours, ,from
fromabout
about1 to11 about
to about
1.5hours, from 10 lymphoma
,
follicular lymphoma, lymphoplasmacytic lym
, extranodal marginal zone lymphoma, mucosa -asso
about 1.5 to about 10 hours, from about 1.5 to about 8 hours, phoma
ciated lymphatic tissue ( MALT ) lymphoma, anaplastic large
from about 1.5 to about 6 hours , from about 1.5 to about 4 cell
lymphoma (ALCL ), Mantle cell lymphoma, Hodgkin's
hours, from about 1.5 to about 2 hours, from about 2 to about lymphoma, non - Hodgkin's lymphoma, and lymphoblastic
10 hours , from about 2 to about 8 hours , from about 2 to 15 lymphoma.
about 6 hours , from about 2 to about 4 hours, from about 4
Example inflammatory diseases include arthritis, rheuma
to about 10 hours , from about 4 to about 8 hours , from about toid arthritis, vasculitis , inflammatory bowel disease , glom
4 to about 6 hours, from about 6 to about 10 hours , from erulonephritis, sarcoidosis, inflammation of the eye, inflam
about 6 to about 8 hours , or from about 8 to about 10 hours . mation of the skin , inflammation of an organ ( e.g. , brain ,
In some embodiments, the contacting is performed from 20 liver, pancreas , heart, lung , stomach , spleen, and the like) ,
about 2 to about 5 hours .
inflammation of the respiratory tract, inflammation of the
In some embodiments, at least one of the polyionic digestive tract, muscular inflammation , inflammation of the
polymers is a polycationic polymer as described herein and lymphatic system , and the like . In some embodiments, the
at least one of the polyionic polymers is polyanionic poly- disease is atherosclerosis. In some embodiments, the disease
25 comprises atherosclerotic plaque.
mer as described herein .
Methods of Use & Combination Therapy
Example autoimmune diseases include, but are not lim
The present application further provides methods of treat- ited to , autoimmune diseases of the heart ( e.g. , myocarditis,
ing a disease or disorder in a subject in need thereof. As used postmyocardial infarction syndrome, postpericardiotomy
herein , the term “ subject ” refers to any animal, including syndrome, subacute bacterial endocarditis ), autoimmune
mammals, for example , mice , rats, other rodents, rabbits, 30 diseases of the kidney ( e.g. , anti-glomerular basement mem
dogs , cats , swine, cattle, sheep, horses , primates , and brane nephritis, lupus nephritis ), autoimmune diseases of the
humans . In some embodiments , the subject is a human . In liver ( e.g. , autoimmune hepatitis , primary biliary cirrhosis ),
some embodiments, the method comprises administering to autoimmune diseases of the lung ( e.g. , antisynthetase syn
the subject a composition provided herein , wherein the drome ), autoimmune diseases of the skin ( e.g. , psoriasis,
composition comprises one or more therapeutic agents. In 35 systemic scleroderma ), pancreatitis , diabetes mellitus type 1 ,
some embodiments, the administration comprising admin- Graves' disease , Sjorgren's syndrome, celiac disease ,
istering a therapeutically effective amount of the one or more Crohn's disease , ulcerative colitis , Lyme disease , Guillain
therapeutic agents.
Barré syndrome, and multiple sclerosis .
As used herein , the term “ treating ” or “ treatment ” refers
The present application further provides a method for
to one or more of ( 1 ) inhibiting the disease ; for example, 40 controlled release of one or more therapeutic agents, com
inhibiting a disease , condition or disorder in an individual prising administering to a subject a composition provided
who is experiencing or displaying the pathology or symp- herein , wherein the composition further comprises the one
tomatology of the disease , condition or disorder (i.e. , arrest- or more therapeutic agents. In some embodiments, the
ing further development of the pathology and / or symptoma- method is performed ex vivo . In some embodiments, the
tology ) ; and ( 2 ) ameliorating the disease ; for example, 45 method is performed in vivo .
ameliorating a disease , condition or disorder in an individual
The present application further provides a method for
who is experiencing or displaying the pathology or symp- delayed release of one or more therapeutic agents, compris
tomatology of the disease, condition or disorder (i.e. , revers- ing administering to a subject a composition provided
ing the pathology and /or symptomatology ) such as decreas- herein, wherein the composition further comprises the one
ing the severity of disease or reducing or alleviating one or 50 or more therapeutic agents. In some embodiments, the
more symptoms of the disease.
method is performed ex vivo . In some embodiments, the
In some embodiments, the disease or disorder is a cancer , method is performed in vivo .
an autoimmune disease or disorder, or an autoimmune
disease or disorder . In some embodiments, the disease is a

cancer .

In some embodiments , the cancer is selected from the

group consisting of pancreatic cancer , bladder cancer , brain

The present application further provides a method of
treating a disease or disorder in a subject in need thereof,

55 comprising administering to the subject a composition pro

vided herein , wherein the composition releases the one or

more therapeutic agents for treatment of the disease . In some

cancer (e.g. , glioblastoma ) , breast cancer , colon cancer, embodiments, the release is a controlled release . As used
endometrial cancer, gastrointestinal cancer, a hematological herein, the term “ controlled release ” refers to the release of
cancer, liver cancer , lung cancer, prostate cancer, skin can- 60 a therapeutic agent over time or in response to a stimulus
cer , stomach cancer, and renal cancer. In some embodi- wherein the release maintains drug levels within an appro
ments, the cancer is breast cancer. In some embodiments, the priate dosage level . In some embodiments, the controlled
cancer is brain cancer. In some embodiments , the cancer is release is a timed release (i.e. , the one or more therapeutic
glioblastoma.
agents are released after a period of time ) or a sustained

In some embodiments, the hematological cancer is 65 release (i.e. , the one or more therapeutic agents are gradually

selected from the group consisting of leukemia and lym-

phoma .

released over a period of time within an appropriate , non
toxic dosage level ) . In some embodiments, the release is a
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delayed release. As used herein , the term “ delayed release ”

The present application further provides a method of

refers to a release that occurs at a time substantially later treating an autoimmune disease or disorder, comprising
than administration of the one or more therapeutic agents administering to a subject in need thereof a composition
provided herein, wherein the composition further comprises
( i.e. , the release is not immediate ).
In some embodiments, the administration comprises con- 5 an immunosuppressant agent. Example immunosuppressant
tacting a diseased cell with a composition provided herein . agents include , but are not limited to , azathioprine, chloram
In some embodiments, the contacting is performed ex vivo . bucil , cyclophosphamide, cyclosporine , daclizumab , inflix
In some embodiments, the contacting is performed in vivo . imab , methotrexate , and tacrolimus. In some embodiments ,
The present application further provides a method of the immunosuppressant agent comprises one or more virus
treating cancer , comprising administering to a subject in 10 strains or particles useful as a vaccine for treating the
need thereof a composition provided herein , wherein the autoimmune disease or disorder. In some embodiments, the
composition further comprises a chemotherapeutic agent. immunosuppressant agent comprises one or more virus
Example chemotherapeutic agents include, but are not lim- strains or particles useful as a vaccine for treating diabetes
ited to , cisplatin , doxorubicin , taxol, etoposide , irinotecan , (e.g. , type 2 diabetes ).
topotecan , paclitaxel , docetaxel , epothilones, tamoxifen , 15 In some embodiments , the methods provided herein fur
5 - fluorouracil, methotrexate, temozolomide , cyclophosph- ther comprise administering one or more additional thera
amide , SCH 66336 , R115777 , L778,123 , BMS 214662 , peutic agents or a radiation therapy. Example therapeutic
gefitinib , erlotinib hydrochloride, antibodies to EGFR , ima- agents for use in combination therapy include , for example ,
tinib mesylate , intron , ara - C , gemcitabine , uracil mustard, therapeutic agents provided herein and anesthetics ( e.g. for

chlormethine,triethylenemelamine
ifosfamide, melphalan
, chlorambucil, pipo- 20 use in combination with a surgical procedure ). Example
, triethylenethiophos- anesthetics include, but are not limited to local anesthetics

broman ,

phoramine, busulfan , carmustine , lomustine, streptozocin , such as lidocaine , procain , and ropivacaine .
In some embodiments, the one or more additional thera
6 - thioguanine, fludarabine phosphate , oxaliplatin , folinic peutic agents are administered simultaneously with a com
acid, pentostatin , vinblastine , vincristine, vindesine , bleo- 25 position provided herein . In some embodiments, the one or

dacarbazine, floxuridine, cytarabine, 6 -mercaptopurine,

mycin, dactinomycin, daunorubicin , doxorubicin , epirubicin , idarubicin , mithramycin , deoxycoformycin, mitomycinC , L - asparaginase, teniposide, 17a - ethinylestradiol ,
diethylstilbestrol, testosterone, prednisone, fluoxymesterone , dromostanolone propionate , testolactone , megestrol
acetate , methylprednisolone, methyltestosterone, prednisolone , triamcinolone, chlorotrianisene, hydroxyprogesterone,
aminoglutethimide, estramustine , medroxyprogesteroneacetate , leuprolide, flutamide, toremifene, goserelin , carboplatin , hydroxyurea , amsacrine, procarbazine, mitotane , mitoxantrone, levamisole , vinorelbine , anastrazole, letrozole,
capecitabine, reloxafine, hexamethylmelamine, bevacizumab , bexxar, velcade , zevalin , trisenox, xeloda, vinorelbine, porfimer, erbitux , liposomal , thiotepa, altretamine,
melphalan , trastuzumab , fulvestrant, exemestane, ifosfamide , rituximab , C225 , alemtuzumab , clofarabine, cladribine , aphidicolin, sunitinib , dasatinib , tezacitabine, Smli ,
triapine, didox , trimidox, amidox , 3 -AP, MDL - 101,731 ,
bendamustine, ofatumumab , and GS - 1101 (also known as
CAL - 101 ) . In some embodiments, the chemotherapeutic
agent is doxorubicin . In some embodiments, the chemotherapeutic agent comprises one or more oncolytic virus
strains or particles.
The present application further provides a method of
treating an inflammatory disease or disorder, comprising
administering to a subject in need thereof a composition
provided herein , wherein the composition further comprises
an anti- inflammatory agent. Example anti -inflammatory
agents include , but are not limited to , aspirin , choline
salicylates, celecoxib , diclofenac potassium , diclofenac
sodium , diclofenac sodium with misoprostol, diflunisal,
etodolac , fenoprofen , flurbiprofen , ibuprofen , ketoprofen ,
meclofenamate sodium , mefenamic acid , nabumetone ,
naproxen , naproxen sodium , oxaprozin , piroxican ,
rofecoxib , salsalate , sodium salicylate, sulindac , tolmetin
sodium , and valdecoxib . In some embodiments , the antiinflammatory agent comprises one or more virus strains or
particles useful as a vaccine for treating the inflammatory
disease or disorder. In some embodiments, the anti- inflam-
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more additional therapeutic agents are administered after
administration of a composition provided herein . In some
embodiments, the one or more additional therapeutic agents
are administered prior to administration of a composition
provided herein .
Devices and Pharmaceutical Compositions
The present application further provides a device com
prising a composition provided herein . In some embodi
ments, composition is formulated as a coating. In some
embodiments, the device is coated in a composition pro
vided herein . In some embodiments, at least one surface of
the device is coated in a composition provided herein . In
some embodiments, the present application provides a
coated device ( e.g. , a coated medical device ) , wherein the
coating comprises a composition provided herein . In some
embodiments, the composition further comprises one or
more therapeutic agents .
In some embodiments , the device is a medical device . In
some embodiments, the medical device is selected from the
group consisting of a stent, a catheter, a syringe , a needle , a
microneedle , a medical implant, a metal rod, a cardiac pace
maker, a surgical staple , a surgical suture, a needle , a
balloon , a bandage, a wound graft, and a cartilage substitute .
The present application further provides a pharmaceutical
composition comprising a composition provided herein and
at least one pharmaceutically acceptable carrier. The phar
maceutical composition provided herein can be prepared as
described herein or elsewhere , and can be administered by
a variety of routes , depending upon whether local or sys
temic treatment is desired and upon the area to be treated .
Administration may be , for example , oral administration . In
some embodiments, the pharmaceutical composition is for
mulated as a tablet , a pill , a powder, a suspension , an
emulsion , or a capsule ( e.g. , a soft or hard gelatin capsule ).
The compositions provided herein comprising one or
more therapeutic agents can be effective over a wide dosage
effective amount. It will be understood , however, that the
amount of a composition comprising the one or more

range and are generally administered in a therapeutically

matory agent comprises one or more virus strains or par- 65 therapeutic agents actually administered and the schedule of
ticles useful as a vaccine for treating a cardiovascular
disease .

administration will usually be determined by a physician ,
according to the relevant circumstances, including the con
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dition to be treated , the chosen route of administration , the potential and dynamic light scattering instrument (Holts
actual therapeutic agent( s ) administered, the age , weight, ville , N.Y., USA) . The particle size was analyzed as an
and response of the individual subject, the severity of the intensity averaged distribution using a scattering angle of
90 ° at 25 ° C. The Smoluchowki model was utilized to
subject's symptoms, and the like.
The present application further provides a tablet coated 5 calculate the zeta potential from mobility measurements . All
with a composition provided herein . In some embodiments, measurements were performed in 0.05xPBS (pH 7.4 ) at 25 °

the tablet further comprises one or more additional therapeutic agents. In some embodiments, the tablet is coated
with a composition provided herein , wherein the composi-

C.
AFM analysis was performed with a Nanocscope Ma
Dimension 3100 SPM system (Digital Instruments, Santa

Mean hydrodynamic diameter and zeta potential were
measured using a Brookhaven NanoBrook ZetaPALS zeta

The buildup of the PLL/ SPS films was confirmed via
UV - Vis spectrophotometry, as shown in FIGS . 1A - B using

tion further comprises one therapeutic agent. In some 10 Barbara , Calif.) operating in tapping mode . This instrument
embodiments , the composition and the tablet each comprise is located in the Nebraska Center for Materials and Nano
one or more independently selected therapeutic agent. In science's Scanning Probe Microscopy.
some embodiments , the composition and tablet each comThe phosphotungstic negative stain method was utilized
prise one or more of the same therapeutic agent. In some for visualization of the LNP system using transmission
embodiments, the composition and tablet each comprise one 15 electron microscopy (TEM) . A drop of each sample was
or more different therapeutic agents.
applied to separate copper grids coated with a carbon film
In some embodiments, the tablet is formulated as a and left to air dry. A 2 % phosphotungstic acid solution was
pharmaceutical carrier. The tablets provided herein can be applied for negative staining, and the samples were analyzed
coated (e.g. , with a composition provided herein ) or other- using a Hitachi H7500 transmission electron microscope .
wise compounded to provide a dosage form affording the 20 The 21 MT- 1 cell culture line was isolated from the
advantage of prolonged action . For example , the tablet can metastatic pleural effusion mammary tumor specimens. The
comprise an inner dosage and an outer dosage component, 21MT- 1 cells were cultured in a - MEM media supplemented
the latter being in the form of an envelope over the former. with 1 % Penicillin -Streptomycin ( PS ) , 1 % L - glutamine, 20
The two components can be further separated by an enteric mM HEPES , 5 % fetal bovine serum (FBS ) , non -essential
layer which serves to resist disintegration in the stomach and 25 amino acids , sodium pyruvate (all listed reagents from
permit the inner component to pass intact into the duodenum Invitrogen ), 12.5 ng/mL epidermal growth factor (EGF) and
or to be delayed in release . Examples of materials that can 1 ug /mL hydrocortisone (both from Sigma ) . This media is
be used for enteric layers or coatings, include , but are not termed " complete 21MT- 1 media ” , (i.e. complete media )
limited to , polymeric acids and mixtures of polymeric acids and the absence of FBS and PS is regarded as “ incomplete
with such materials as shellac , cetyl alcohol, and cellulose 30 21MT- 1 media” (i.e. incomplete media ). SKBR3 ( ATCC
acetate .
HTB30 ) , a human HER2 + invasive mammary gland adeno
When employed as pharmaceuticals, the compositions carcinoma cell line , were cultured in analogous conditions
provided herein can be administered in the form of phar- as the 21 MT - 1 cells except without the addition of EGF or
maceutical compositions; thus, the methods described herein hydrocortisone. MCF10A (ATCC CRL - 10317 ) , human nor
can include administering pharmaceutical compositions pro- 35 mal breast tissue cell line , were cultured in DMEM/F12
vided herein .
(Mediatech ) and supplemented with 1 % L - glutamine , 1 %
Penicillin
- Streptomycin , 5 % Horse Serum , 0.1 ng /ml chol
EXAMPLES
era toxin ( Sigma ) , 0.5m /ml hydrocortisone, 10m /mL insulin
(Sigma ), and 0.02 ng/uL rhEGF ( Sigma ) . The cells were
The invention will be described in greater detail by way 40 kept in aseptic conditions , and grown in an incubator at 37 °
of specific examples . The following examples are offered for C. with 5% CO2
illustrative purposes , and are not intended to limit the
Flow cytometry was performed using a FACSCantoII
invention in any manner . Those of skill in the art will readily from Becton Dickenson ( Franklin Lakes, N.J. , and USA) .
recognize a variety of non- critical parameters which can be
The difference between experimental groups was ana
changed or modified to yield essentially the same results . 45 lyzed by a one - way analysis of variance ( ANOVA ) and by
General Materials and Methods
a subsequent Turkey's multiple comparison test in Sigma
For polyelectrolyte multilayer (PEM) fabrication , poly- Plot Software. For statistical analysis of all data , p <0.05 was
L -lysine ( PLL ) hydrochloride with a molecular weight regarded as the lowest acceptable threshold for significance.
greater than 30,000 Da and poly ( sodium styrene sulfonate )
( SPS ) with a molecular weight of ~ 70,000 Da were pur- 50
Example 1. Polyelectrolyte Multilayer Base
Fabrication
chased from Sigma Aldrich ( St. Louis , Mo. , USA) . For
liposome assembly and nanoparticle surface conjugation,
hyaluronic acid ( HA) with a molecular weight of 1.65 MDa ,
A polyelectrolyte multilayer (PEM) base structure of PLL
1,2 -dipalmitoyl-sn - glycero - 3 -phopshoethanolamine
and SPS was constructed by sequential adsorption of the
( DPPE ) , cholesterol (CHOL ) , and 1 - ethyl -3- ( 3 - dimethyl- 55 polyelectrolytes on top of an oxygen plasma treated surface
aminopropyl ) carbomiide ( EDAC ) were purchased from (glass slide or tissue culture plate ) . The negatively charged
Sigma . Additionally, L a -phosphatidylcholine (PC ) and Top surface was first incubated with 0.5 mg/mL PLL (20 UM
Fluor fluorescently tagged cholesterol were purchased from PBS , 0.15M NaCl ) for 20 minutes , followed by numerous
Avanti Polar Lipids ( Alabaster, Ala . , USA) . For Capillary washing steps with deionized water ( DI ) to remove excess
Force Lithography (CFL ) , PDMS elastomer (SYLGARD 60 polymer, and subsequent incubation with 10 mM SPS (0.1M
184 Silicone Elastomer Base) and PDMS cross linker (SYL- NaCl ) for another 20 min to create a single PEM bilayer.
GARD 184 Silicone Elastomer Curing Agent) were pur- This process was performed 4.5 times to create the PLL
chased from Dow Corning Corporation ( Midland, Mich . , topped PEM base structure (PLL/ SPS ) 4.5 . When used for
USA ) . Fluorosilane ( Trichloro ( 3,3,3 - trifluoropropyl ) silane ) cell culture experiments, the PEM base structure was UV
was purchased from Sigma.
65 sterilized for 8-12 hours in a biosafety cabinet.
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Example 4. Adsorption Process for HALNPs
absorbance at 220 nm ( finger print spectra of SPS ) and
fluorescence (Rhodamine tagged SPS ) . As is shown in FIGS .
1A - B , multilayered PLL/ SPS coatings displayed linear
To monitor the adsorption of HALNPS , 0.15 mass % of
increase in UV -absorbance spectrum with each successive Top Fluor fluorescently conjugated cholesterol was added to
double - layer addition , thus validating PEM film construc- 5 the initial lipid stock to effectively tag the nanoparticles.
tion . Atomic force microscopy experimentally confirmed a Then , to initially determine if the HA - LNPs could success
high degree of surface uniformity on the (PLL/ SPS )4.5 base fully adsorb onto a PEM surface, 180 ug lipid / cm² was
platform signifying an ideal surface for nanoparticle depo incubated with both PLL ( PLL/ SPS ) 4.5 and SPS (PLL/
sition, as is shown in FIG . 1C .
SPS ) 4.5 topped base layers fabricated in a 12 well plate for
10
three
hours at room temperature. Following incubation , the
Example 2. Preparation of HA Coated Liposomes
surfaces were washed 3x with 20 mM HEPES and visual

(HALNPs )

ized with an Axiovert 40 CFL Zeiss ( Jena, Germany)

Multilamellar vesicles (MLVs) composed of PC , DPPE ,

Inverted Microscope with fluorescent filter, and the images
were captured with a Progres C3 Jenoptick camera . Follow

Peer et al . , Science , 2008 , 319 , 627-630 ; and Hayward et al ,
Journal
of BiomedicalNanotechnology, 2016 , 12 : 554-568) .
The MLV solution was then extruded through progressively
smaller
sizesabove
withtheaa mini
extruder apparatus
( Avanti membrane
Polar Lipidspore
) kept
gel transition
tempera
ture of the lipids at 65-70 ° C. to reach a final hydrodynamic
diameter of 80-100 nm (LNP ) . These nanoscale LNPs were
purified by ultracentrifugation ( 1.5 hr., 135,000 g) to remove
lipid debris and were re -suspended in borate buffer (pH 8.6 ) .
To covalently coat the nanoscale LNPs , HA was dissolved in
sodium acetate buffer ( pH 5 ) , activated with EDAC at a
mass ratio of 1:20 ( HA : EDAC ) at 37 ° C. ( pH ~4 ) for 2 hours
( see e.g. Kleiner et al . , Journal of Controlled Release, 2014 ,

added on top of the anionic nanoparticle monolayer follow
ing previously described adsorption protocol with the sole
procedure change of using 20 mM HEPES for wash steps in

and
CHOLdryin film
a (3method
: 1 : 1) molar
ratio werereported
created( seebye.g.the, 15 ing deposition of theHALNPs, a capping layer consisting of
traditional
as previously
an addition 2.5 bilayers of PLL and SPS , (PLL/ SPS ) 2,5:, was

20 place of DI water. The capping layer was added sequentially

by hand in an aseptic environment to ensure sterile condi
tions . Validation of the selective deposition of negatively

charged HALNP on positively charged PLL is shown in FIG .

2A .
25

181 , 1-10) , and mixed with the purified LNPs overnight to 30

promote amide bond formation (HALNPs ) . Separation of
the resulting HALNPs from excess reagents in solution was
achieved by washing three times using ultracentrifugation .
Following purification , the particles were aliquoted , snap

frozen
in Chamber
ethanol with
dryDryiceSystem
, and lyophilized
Labconco
Freeze
(Kansas Cityusing
, Mo.a, 35

USA) ( see e.g. , Puranik et al . , International Journal of
Pharmaceutics, 2013 , 441 , 665-679 ) . The lyophilized par
ticles were stored at -80 ° C. until use .

Example 3. Directed Deposition of HALNPs onto

40

PEM Films

To determine the extent of the interaction between the

HALNPs and PLL for potential ionic driven adsorption, the
two components were mixed in PBS and measured the zeta 45
potential and hydrodynamic diameter were measured , and
are summarized in Table 1. From this analysis it was found
a mass ratio of 1 : 0.1 (Lipid : PLL ) was sufficient to com

pletely mask and reverse the charge of the HALNPs .
TABLE 1

Dynamic Light Scattering and Zeta Potential
Analysis of Representative LNP systems

Sample ID

( Lipid : PLL mass
ratio )

Hydrodynamic
Diameter

Polydispersity

Zeta
Potential

( nm )

Index

95.1 + 0.6

0.087

164.9 + 1.5
175.9 + 7.5
235.2 + 8.5

0.198
0.233
0.278

HALNP - PLL

310.6 + 19.0

0.310

22.74 + 0.64

HALNP - PLL

363.0 + 31.0

0.360

23.45 + 0.62

(mV )

50

Example 4A . Rehydration ( Entrapment) Protocol
and Cargo Encapsulation Quantification
Lyophilized HALNP particles were rehydrated with 1 /10th
of the original solute volume composed of nuclease free
water containing the cargo (e.g. , FITC -Dextran , miRNA ),
followed by quick vortex agitation to ensure the full quantity
of lyophilized powder was hydrated . After total rehydration
the mixture was left to rest for 30 minutes to allow for lipid
membrane re - assembly. Following this rest period , PBS
solution was added to the sample to match the initial
pre - lyophilization volume and un -encapsulated drug was
removed by ultracentrifugation ( 140,000 g , 4 ° C. , and 1.25
hr.). For encapsulation efficiency determination of the FITC
tagged Dextran (FD ) ( Sigma) cargo, fluorescence at 495 nm
em / 520 em was measured in the presence of 0.1 % Triton
X - 100 detergent to disrupt the lipid bilayers.
Following the lyophilization process and subsequent
rehydration in the presence of physiological buffer, the
HALNPs particle size increased minimally and underwent
no significant change in net surface charge, indicating that
all HA remained on the outside of each particle during the
bilayer reformation process. This step was crucial to ensure
that the HALNPs would not be structurally altered during
the entrapment procedure. TEM characterization of the LNP

system exposed that 1 ) the surface roughness increased post
crosslinking to HA, further providing validation of an appre

ciable coating of the biopolymer on the nanoparticle surface,
and 2 ) that HA is an effective cryoprotectant for LNPs and
55 is required to keep the nano - dimensions of the platform
during the drug entrapment process, as shown in FIG . 8A .
A range of molecular weight FITC - tagged Dextran ( FD ;
10 , 20 , and 70 kDa) were successfully encapsulated and
used to demonstrate that the diameter of the HALNP carrier
60 post drug entrapment is not aa function of the size of the cargo
in the aqueous interior of the nanoparticle , as well as the
versatility of the carrier to entrap a broad range of cargo
sizes . The tumor suppressor miR125a - 5p was also success
fully encapsulated in an analogous manner with additional
65 precautions taken to avert RNAse driven degradation. Com
prehensive data on particle size , surface charge, and cargo
9

LNP
HALNP
HALNPDOX
HALNP - PLL

( 1 : 0.1 )
( 1 : 0.5 )

( 1 : 1.0 )

-9.46
-23.29
-17.05
20.08

+ 0.31
+ 4.70
+ 2.40
+ 0.42

entrapment is shown in Table 2. Particle size distributions of
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the nanoparticle systems HALNP, HALNP -FD ( 10 , 20 , and
70 kDa , respectively ) , and HA - LNP -miR125a - 5p were also
probed to confirm that in each case a monodisperse popu-

placed in a new desiccator, which was alternately evacuated
by vacuum pump and re -pressurized to remove any bubbles
in the liquid PDMS . Once all bubbles were eliminated, the

lation of particles was obtained , as shown in FIG . 8B .
TABLE 2
Quasi Elastic

Light Scattering

Hydrodynamic
Diameter
LNP
HALNP
HALNP

Poly
dispersity
Index

Drug

Potential
Zeta
Potential

Encapsu
lation
Efficiency
(% )

( nm )

( PI )

(mV)

93.6 + 0.4
157.2 + 1.4
182.1 + 1.2

0.061
0.105
0.201

-9.46 + 0.31
-38.07 + 0.35
-41.24 + 0.57

185 ? 200

0.15 ? 0.21

197.5 + 1.7

0.182

Rehydrated
HALNP

Electrokinetic

-41

-43

35

55

10, 20, or

70 kDa FD
HALNP

-43.24 + 0.57

24.1 + 4

miR125a

With a known amount of fluorescent drug present during

mixture was cured in the oven at 60 ° C. for 24 hours . After
5 curing, the PDMS was removed from the silicone master

pattern with a scalpel , and the stamps were cut to size .
PDMS micro -patterned line stamps were cut into rectan
gular sections with open channels on two out of four faces .
The stamps were cleaned with liquid hand soap and DI
10 water, and then blown dry with air. They were then treated
in an oxygen plasma cleaner for one minute in order to
induce a negative charge on their surface. The stamps were
then placed pa down on of polyelectrolyte multi
layer (PEM) coated glass slides ( PLL/ SPS ) 44 , and stabilized
15 with a weight ( 90 g ) placed on top . 10 uL of 0.5 mg /mL PLL
solution was evenly applied to the edge of the stamp with a
pipette, at the contact point of the open channels and the
PEM coated slide . By capillary force and charge/charge
interactions, PLL solution was drawn into the channels . The
20 patterns were allowed to dry for twenty - five minutes before
the stamps were removed . Following this dry time the
patterned PLL was UV sterilized for 8-12 hours , coated with
and capped with the capping layer prior to cell

the entrapment procedure, a standard curve was utilized to

culture work .

of Human miRIDIAN miR125a - 5p Mimic or scramble miR
negative control (both from Dharmacon ), a specific RNA
binding dye, Quant - it Ribogreen RNA Assay ( Invitrogen ),
was utilized in the presence and absence of 0.1 % Triton
X100 detergent following a previous protocol ( see e.g. ,
Landesman -Milo et al , Cancer Lett. 2013 , 334 : 221 ) . The
RNA binding dye was unable to penetrate intact lipid
membranes, and therefore in the absence of detergent only

to the PLL regions compared to SPS films which is indica
tive of the fluorescent patterns formed on the PEM surfaces.
Example 7. Affinity Assay and Saturation Curve for

determine the amount entrapped. For encapsulation analysis 25 As observed in FIG . 2A , the HALNPs selectively adhered

HALNP Loading
To evaluate the loading of HALNPs into the PEM plat
form , a dual affinity and saturation curve assay was system
the fluorescence of the un - entrapped miRNA was measured . atically implemented to determine optimum and saturated
In the presence of detergent, the total fluorescence was 35 deposition conditions . First , a standard curve of known
measured to determine the % encapsulation . Additionally, by fluorescent HALNPs mass ( termed lipid mass) was used to
30

comparing the total fluorescence to a RNA standard fluorescence curve, the exact concentration of miRNA entrapped

create a fluorescent standard curve . Then , two 48 well plates
were coated with a PEM base layer. One plate was coated
with a PLL topped layer ( PLL/ SPS )4.5 , while the other was
was determined .
40 coated with an SPS topped layer (PLL/ SPS )4 . Then , a range
HALNP concentration , 1 to 800 ug /ml, was incubated with
Example 5. Atomic Force Microscopy ( AFM )
the 48 well plates for 3 hours at room temperature covered
AFM was used to visualize the PEM base platform pre in foil . Following this incubation time , the supernatants from
and post deposition with HALNPs . Three samples were each well were read against the standard curve to determine
prepared : 1 ) the PEM base platform (PLL /SPS ) 4.5,) 2 ) HAL- 45 concentration of un - attached nanoparticles, and the percent
NPs deposited on the base platform without capping layer, difference between the PLL and SPS topped substrate wells
and 3 ) deposited HALNPs on the (PLL/ SPS ) 4.5 base with a (at analogous nanoparticle incubation concentration) was
( PLL / SPS )2,5 capping layer. All samples were allowed to air used to determine the affinity of the HALNPs for that
dry in an oven at 25 ° C. overnight. Both height and phase particular surface . The concentration of embedded particles
50 deposited on the plate was also measured by reading the 48
( deflection ) images were obtained .
well plate in a Biotek Synergy 2 Multi -Mode Plate Reader
Example 6. Capillary Force Lithography (CFL ) to
( Winooski, Vt., USA ) to confirm conservation of mass (ex .
Pattern HALNPs
495 nm , em . 520 nm ). To determine the HALNP saturation
conditions of the PLL topped base platform , the 1 ) super
To further investigate the differential adhesion of HALNP 55 natant and 2 ) nanoparticle embedded plate data from the
on PLL surfaces over SPS surfaces, PLL was patterned on affinity assay was used to determine the exact amount of
( PLL/ SPS )4 films using capillary force lithography (CFL ) mass loaded per area as a function of the nanoparticle
and exposed fluorescently labeled HALNPs onto these films. loading concentration . From this information, the saturation
The silicone master pattern was secured to the bottom of point of HALNPs was determined from a nonlinear regres
2

a large cell culture dish , and was placed in a desiccator with 60 sion analysis via Sigma Plot Software (San Jose , Calif.,
an open vial of fluorosilane . The desiccator was evacuated

USA) .

by vacuum pump , creating a partial pressure of fluorosilane.
The affinity assay between HALNP and both ( PLL/ SPS ) 4
Meanwhile, PDMS elastomer and cross linker were com- and (PLL/ SPS )4.5 was performed over a lipid range of 0.1 to
bined in a ( 9 : 1 ) mass ratio , and stirred vigorously by hand 1000 ug/cm² utilizing analogous deposition conditions
for five minutes. The silicone master pattern was removed 65 described previously. By analyzing the percent difference in
from the desiccator, and the PDMS mixture was poured over lipid adhesion between the PLL and SPS topped platforms
the master pattern . The PDMS covered master pattern was over the range of lipid concentration, it was estimated that
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a minimum and maximum lipid concentration of 1.6 ug/cm² capping layer, and also validated the deposition of the
and 31.6 ug / cm² is necessary to overcome kinetically hin- capping layer on top of the HALNPs .
dered deposition and reduction in embedment efficiency due
Example 9. Flow Cytometry
to limited surface area , respectively, as is shown in FIG . 3A .
A saturation experiment analogous to a Michealis -Menton 5
Kinetics curve was then performed to determine the maxiTo study the effect of nanocarrier immobilization in PEM
mum HALNP possible to load per unit surface area , as is films on cellular uptake , the bolus delivery of fluorescently
shown in FIG . 3B . An exponential increase followed by tagged HALNPs was compared to the HALNPs immobi
saturation conditions was observed for the HALNP loading lized in the PEM films with the (PLL/ SPS ) 2,5 capping layer
with a maximum loading of 5 ug/cm HALNPs achieved . At 10 (HALNP - PEM ) . For this experiment, patient derived
a loading concentration of 31.6 ug/cm² , the HALNP depo-

21MT- 1 metastatic breast cancer cells isolated from the

sition efficiency was calculated to be 16 % . This information metastatic pleural effusion were used as a model system . A
provides the ability to load a precise amount of HALNP time course study was performed via flow cytometry to
within the PEM platform , and the capability to control the determine the kinetics of cell uptake of the fluorescently
concentration of any encapsulated hydrophilic or hydropho- 15 tagged HALNPs when delivered in the bolus form compared
to using the HALNP - PEM platform , as shown in FIGS .
bic cargo within the lipid bilayer of the nanocarrier.
Next the release kinetics of the HALNPs from the PEM
4A - 4B .
system was determined , both with and without the capping
A 12 well culture plate was first plasma treated and
layer, as is shown in FIG . 3C . It was demonstrated that deposited with a PEM base of ( PLL/ SPS )4.5 . This base
approximately 60 % and 20% of the adsorbed HALNPs were 20 platform was then UV sterilized overnight. Filter sterilized
released in the uncapped and capped PEM systems , respec- HALNPs with 0.15 % Top Fluor fluorescent cholesterol were
tively, over the course of seven days. In addition , the capped then deposited on the PLL surface applying saturation
HALNP - PEM system demonstrated a linear release profile conditions , followed by the addition of the capping layer ( 5
without an initial burst release that was observed in the early ug / cm²; total HALNP loading in a 12 well =20.05 ug
stages of the uncapped system . This indicated that the 25 HALNP per well ) . Each well was then seeded with 170,000
capping system atop the immobilized HALNP on PEM films 21MT- 1 cells and placed in the incubator overnight to
provides the ability to achieve a highly controlled and promote cell attachment. At 12 , 24 , and 36 hours , the cells
were washed 3x with sterile 1xPBS , trypsinized , and trans
sustained nanocarrier release profile.
ferred to flow cytometry tubes. Theses samples were then
Example 8. Fluorescent Recovery after
30 analyzed for fluorescence in the green channel (ex . 495 nm ,
Photobleaching (FRAP )
em . 520 nm ; 10,000 total events/read ) against control cells .
Both per cell fluorescence and total % population FITC
A HALNP loading of 5 ug lipid / cm² was deposited onto positive information was measured . Additionally, bolus
a ( PLL /SPS )4 5 base layer utilizing the previously mentioned form HALNPs , free nanoparticles not bound to a substrate ,
saturation protocol. Then, a portion of the deposited HALNP 35 were also incubated with 21 MT- 1 cells in an analogous
layer was photo bleached with an Axiovert 40 CFL Zeiss manner ( same seeding density of cells and concentration of
( Jena, Germany) Inverted Microscope with a FITC filter for 20.05 ug HALNPs per well ) to compare the substrate
5 minutes ( see e.g. , International Patent Application No. WO mediated and bolus form intracellular delivery of HALNPs
9

2007/146001 ) . The fluorescent microscope was then shut off as a function of time .
for a designated amount of time ( 10 or 30 minutes) to allow 40 At 12 hours , it was found that 55 % of the cells were

for the assessment of nanoparticle mobility. After this wait positive for HALNP uptake from the HALNP - PEM plat
time , the microscope was turned back on and aa fluorescent form compared to 81 % positive cells from the bolus deliv
image was immediately captured. This procedure was per- ery . Also at 12 hours, the per -cell fluorescent intensity of the
formed both with and without a (PLL /SPS ) 2,5 capping layer cells on the HALNP - PEM was 11 fold higher than control
over the HALNP deposited monolayer to compare the effect 45 cells as compared to 26 fold higher than control for the bolus
of nanoparticle confinement on mobility. All analyses were delivery . At 36 hours, the percent cell population for the
performed in wet conditions, in 20 mM HEPES buffer at pH HALNP - PEM system increased to 60 % while the bolus
7.4 at room temperature. A control film without labeled delivery remained unchanged. However, the per -cell fluo
nanoparticles has also been included to discern any back- rescent intensity in the HALNP - PEM increased to 17 fold
ground fluorescence.
50 higher than control cells ( 60% increase) compared to bolus
FRAP experiments on fluorescently tagged HALNPs delivery that decreased to 8 fold higher than control ( 68 %
deposited atop ( PLL/ SPS )4.5 films demonstrated that the decrease ). These results demonstrate that the HALNP - PEM
HALNPs were not completely immobilized and were par- system has a sustained release of the HALNPs while the
tially mobile on the PEM surface after 10 minutes, as is bolus delivery system has burst release kinetics with sub

shown in FIG . 2B . As aa result, the net immobilization of the 55 sequent rapid intracellular degradation . At 60 hours, 80% of

particles was increased via an additional ionic interaction the cell population was positive for HALNP uptake in the
and physical barrier in the form of a (PLL/ SPS ) 2,5 " capping HALNP - PEM platform which is comparable to the bolus
layer " above the adsorbed HALNPs ( i.e. , an additional delivery at 12 hours . This confirms that the HALNP - PEM
polyelectrolyte multilayer ). The FRAP experiment was platform performs on par with the bolus delivery method in
repeated on the HALNP - PEM surface with the capping layer 60 regards to the efficiency of cell uptake. Also at 60 hours the
and found that that this additional barrier completely per -cell fluorescence in the HALNP - PEM system increased
impeded the migration of the HALNPs within a PEM by 6 % compared to a 40 % decrease for the bolus delivery ,
sandwich for both 10 min and 30 min, as shown in FIGS . further confirming sustained delivery with the HALNP
2B - 2C . Atomic force microscopy of the HALNP embedded PEM .
PEM was also performed pre- and post- addition of the 65 To investigate the release mechanism of the HALNPs
capping layer. This demonstrated that the adsorbed nanopar- from the PEM platform , fluorescent microscopy was
ticles remained spherical pre- and post- addition of the

employed at different time intervals, as shown in FIG . 4C .
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It was observed that the fluorescent cells increased gradually

rimetric assay assesses cell health as a function of the

release profile demonstrated with the flow cytometry data .

two - step procedure was implemented for precise loading of

with each time interval, which is similar to the HALNP

This experiment provided information regarding 1 ) validation of the intracellular delivery of the HALNPs and 2 )

mitochondrial conversion of MTT salt to Formazan . A

5

DOX into the HALNPs and then into the HALNP - PEM
platform .

evidence regarding the release of the HALNPs from the

First aa solution of 500m of DOX in 0.05xPBS was used

HALNP - PEM platform . The outcome of this experiment in
combination with flow cytometry indicated that HALNP
release from the HALNP - PEM platform may be a cell

to rehydrate a lyophilized vial of HALNPs and excess

enhanced process .

Example 10. Encapsulation of Doxorubicin ( DOX )
in HALNPs ( HALNPDOX )

( un - encapsulated) DOX was removed using ultracentrifuga
10 tion ( 140,000 g , 1.25 hrs, 4 ° C. ) . A standard curve of known
DOX concentrations was employed to determine the total
amount of DOX encapsulated in the HALNP sample

(“ HALNPDOX ” ). The initial vial of HALNPs ( 1 mg Total
To determine the efficacy of delivering packaged drugs 15 Lipid) concentration was known, thus both the total amount

within the HALNP embedded nanocarrier, HALNPs were of encapsulated DOX and lipid were fully determined .
immobilized with encapsulated doxorubicin ( DOX ) within Secondly, the HALNPDOX particles were adsorbed onto the
the HALNP - PEM platform .
Vials of lyophilized HALNPs were brought to room (PLL / SPS )4.5 base platform ensuring the amount of lipid
temperature and rehydrated with 110 of the original pre- 20 required to achieve a specified dosage of DOX was below
lyophilized volume with DOX dissolved in 0.05xPBS . the saturation conditions of the lipid as shown in FIG . 3B .
These vials were then quickly vortexed to hydrate the entire The potency assay was run between 2.5 ug /mL DOX and 0
dry lipid film , and left to rest for 30 minutes on a shaker table
to mediate lipid membrane re -assembly and optimum DOX ug/ml DOX.

entrapment ( HALNPDOX ) . Following the entrapment pro 25
pre - lyophilized volume . Un -encapsulated DOX was
removed by ultracentrifugation ( 140,000 g , 4 ° C. , and 1.25
hr.) and subsequent wash steps with 1xPBS . To determine
the amount of encapsulated chemotherapeutic in the aqueous 30
core of the HALNPs , the natural fluorescence of DOX ( ex .
470 nm , em . 585 nm ) was measured in the presence of 0.1 %
Triton X - 100 detergent to disrupt the lipid bilayers and
compared to aa standard curve of known DOX concentration.
Following excess DOX removal, and quantification of total 35
internal DOX payload, the final mass ratio between Lipid
(HALNP ) and DOX was 3.125 : 1 . Therefore, the maximum
loading of DOX encapsulated into the aqueous core of the
HALNPs and then subsequently loaded onto the (PLL/ 40
SPS )4.5 based on lipid saturation of the PEM was 1.6 ug
cedure, additional 1xPBS was added to bring the vials to the

DOX/ cm² .

Following purification, the final mass ratio between Lipid

and DOX was 3.125 : 1 . Therefore, for the 2.5 ug/ml DOX
concentration samples (highest concentration tested in

potency assay ) , 3.9 ug HALNPDOX was adsorbed per well
to achieve the desired DOX concentration ( well volume=0.5
mL ) . This similar reasoning was used for all lower concen
trations of HALNPDOX loading as well . The only differ
ence in this loading procedure compared to empty HALNPs
was the increase in the deposition incubation time from three
hours at room temperature to overnight at 4 ° C. to ensure
complete embedment of the HALNPDOXs as well as pro
tect the activity of the DOX . Supernatant samples were
removed following the adsorption protocol to ensure all
particles deposited onto the (PLL /SPS )4.5, 5 base platform . In
addition , DLS and Zeta potential analysis of the HALNP
DOX particles was analyzed to ensure the encapsulation of
the DOX did not significantly alter with the size or charge

of the HALNPs ( and therefore the adsorption process ). The
(PLL /SPS )2.5
, capping layer was added immediately after the
45 HALNPDOX adsorption .
The kinetics of release for the HALNP nanocarrier from
21MT- 1 cells were seeded at a density of 32,000 cells/well
the PEM platform with and without a (PLL /SPS )2. capping in three 48 well plates with different DOX configurations: 1 )

Example 11. Cargo (DOX ) and Carrier ( HALNP)
Release Kinetics from the PEM Platform

layer was assessed by employment of a fluorescent plate PEM platform with embedded HALNPDOX [ (PLL/ SPS ) 4.5
reader. The PEM system embedded with HALNPs was (HALNPDOX )(PLL / SPS) 2,5 ), 2 ) Bolus form HALNPDOX,
incubated in 1xPBS at room temperature. At specific time 50 and 3 ) free non - encapsulated DOX . After a 24 hours incu

points, the nanoparticle release medium was replaced to bation time between the three systems and the 21 MT - 1 cells ,
acquire samples and to ensure infinite sink conditions were the media was aspirated and 5 mg/mL MTT working solu
maintained . Both supernatant and the HALNP embedded tion was added and incubated for 2 hours at 37 ° C. Cells
plate data (utilizing the established saturation conditions ) were then lysed with lysis buffer ( acidified IPA ) and the
were analyzed to confirm conservation of mass ( ex. 495 nm , 55 absorbance was measured at 570 and 620 nm using a
em . 520 nm ). Release kinetics of HALNP encapsulated Beckman Coulter AD340 plate reader ( Indianapolis, Ind . ,
DOX from the capped and non- capped PEM platform was USA) . Percent viability was determined by normalization of
performed in the analogous manner utilizing the natural

fluorescence of the chemotherapeutic ( ex . 470 nm , em . 585

nm ) in comparison to a standard curve .
Example 12. Potency Assay

The DOX concentration lethal to 50 % of the 21 MT - 1 cells

the 570/620 absorbance ratio to the control untreated cells

60

andFIG
positive
control dead cells .
. 5 and Table 3 each summarize the results determined
from the potency assay ( MTT assay) using 21MT - 1 meta
static breast cancer cells (at 24 hours ) comparing three

distinct delivery methods: 1 ) free DOX , 2 ) bolus delivery of

DOX encapsulated in the aqueous core of HALNP nanopar

( LC50 ) was determined utilizing the MTT ( 3- (4,5 -dimeth- 65 ticles (HALNPDOX Bolus ) , and 3 ) HALNPDOX embedded
yldiazol - 2 -yl ) 2,5 -diphenyl tetrazolium bromide) assay kit into the (PLL/ SPS ) 4.5 base with capping layer (HALNP
from Life Technologies ( Carlsbad, Calif., USA) . This colo- DOX -PEM) .
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of HALNPs above the patterned layers was maintained . At
60 hours, the localization of the pattern was partially dis
Potency Assay Data
persed due to the proliferation and migrating metastatic
breast cancer cells . This experiment further strengthened the
Delivery Method
LC50 ( ug /mL )
5 hypothesis that the HALNP - PEM provides local delivery via
Free DOX
0.191 + 0.0301
a cell dependent uptake mechanism .
0.136 + 0.0248
HALNPDOX Bolus
The same experiment was also performed using DOX
0.197 + 0.0237
HALNPDOX - PEM
encapsulated inside the patterned HALNP - PEM system to
determine if the local delivery of an active therapeutic was
The
HALNPDOX
achieved
higher
potency
due
to
the
10
also
possible using a liposome embedded PEM platform .
potentially faster uptake by the cancer cells compared to free First , HALNPDOX was adsorbed onto the patterned PLL
DOX and HALNPDOX - PEM . It is hypothesized that the followed by subsequent addition of the capping layer. 12
HALNPDOX - PEM platform has a higher LC50 value com hours after seeding of 21 MT- 1 cells , a local uptake of the
pared to HALNPDOX bolus because at 24 hours not all HALNPDOX particles was dependent upon the nanoparticle
HALNPs immobilized within the PEM films are released . 15 deposition pattern was observed , as shown in FIG . 73. A
As a control, a potency assay on empty HALNPs (no DOX ) time point of 12 hours was selected to demonstrate the
was performed to demonstrate that the lipid nanocarrier is a spatial release and uptake of DOX by the cells residing atop
non - toxic delivery system . The DOX apotency assay vali- the HALNP embedded regions and to ensure the cells were
dated that the HALNP -PEM system is a useful platform for still alive .
a controlled release of drugs encapsulated within the HAL- 20
NPs without negatively affecting the potency of the drug.
Example 14. Fluorescent Microscopy and Plate
Next the release profile of DOX from the HALNPDOXReader Quantification of HA - LNP - FD Delivery to
TABLE 3

PEM was investigated with and without the capping layer.

Breast Cell Lines

The release of DOX in both the supernatant and the PEM

platform was monitored via fluorescence as a function of 25 21MT- 1, SKBR3 , and MCF10A cells were plated in 12
time , as shown in FIG . 6. It was observed that without the well plates at a seeding density of 100,000 cells/well and left
capping layer, DOX was released from the PEM surface in overnight in complete media to facilitate cell attachment.
a burst release fashion leading to over 60 % release by 36 The next morning the media was switched to incomplete
hours. The addition of the capping layer to the HALNP- media and 70 pmol of 20 kDa FD either encapsulated inside
PEM platform altered the DOX release kinetics and led to a 30 HALNPs or in the free form (i.e. , no nanocarrier) was added
linear release profile almost identical to the empty fluores- to designated wells . After aa 5 -hour incubation time , the cells
cent HALNP release , signifying that the majority of DOX were washed three times with 1xPBS followed by visual
released was associated with a HALNP nanocarrier. This ization with a fluorescent microscope and quantification of
data further demonstrates that the capped PEM platform is FD uptake by a fluorescent plate reader. Both the HA -LNP
an improved system for the controlled and linear release of 35 FD and free form FD samples were compared to control
therapeutic cargo.
cells with no FD added .
In an additional example , 21MT- 1 cells were transfected
following the previously stated protocol with either HALNP
Example 15. Live Cell Confocal Microscopy
mediated delivery of miR125a - 5p ( 50 pmol ) or HALNP
mediated delivery of scramble miR ( 50 pmol ) . 72 hrs post 40 Two separate experiments were performed using live cell
9

transfection , the cell media was removed and 5 mg /mL MTT confocal microscopy: 1 ) intracellular delivery of 20 kDa FD
salt was added and incubated for two hours at 37 ° C. The by HA - LNPs ; and 2 ) analysis of the intracellular fate of the
cells were then lysed with lysis buffer ( acidified IPA ) and the HA - LNPs following endocytosis. In both cases , 21MT- 1
absorbance was measured at 570 and 620 nm using a cells were grown to 80 % confluency on 35 mm glass bottom
Beckman Coulter AD340 plate reader (Indianapolis, Ind . , 45 dishes (Mattek ). Experiment 1) followed analogous proce
USA) . The change in proliferation was determined by nor- dures previously described involving cellular incubation
malization of the 570/620 ratio to the control untreated cells . with 165 pmol of 20 kDa FD encapsulated inside HALNPs
for five hours. Experiment 2 ) employed HALNPs tagged
Example 13. Spatial Control of HALNP
with 0.15 mass % Top Fluor Cholesterol ( Avanti) in the lipid
Immobilization on the HALNP - PEM Platform
50 bilayer as a tracker, a five hour incubation of the tagged
Enables Local Delivery
particles with 21MT- 1 cells , and lysosome staining by
Lysotracker Red DND 99 (Life Technologies ). In both
To decipher the mechanism of HALNP delivery from the experiments the cellular nuclei were stained by Hoescht
HALNP - PEM platform to cells , the spatial uptake of the Nuclear Stain 33342 ( Pierce ). Following the HA - LNP - FD or
nanocarrier was investigated. The purpose of this experi- 55 HA-LNP -tagged incubation and subsequent staining proce
ment was to determine if preferential uptake will occur with dure, the cells were washed three times with 1xPBS and
21MT- 1 breast cancer cells seeded on top of the HALNP visualized with an Inverted confocal microscope (Olympus
patterns compared to the cells attached on the non -HALNP IX 81 ) at the UNL Microscopy Core Research Facility .
areas . CFL was used to pattern HALNPs tagged with green
Example 16. Competition Assay (HA
fluorescence atop PEM base films. 21MT- 1 cell adhesion to 60
the HALNP patterned PEM system with and without the
Pre - Treatment)
capping layer signified that the capping layer mitigates
heterogeneous cell attachment. At 12 hours post cell seed21 MT - 1 cells were seeded in a 12 well plate with a
ing , pattern dependent cellular uptake with the cells atop the seeding density of 100,000 cells /well and incubated over

HALNP patterns having higher uptake of the particles 65 night to stimulate attachment. The next morning, 250 ug HA
compared to those not on the patterns was observed , as

shown in FIG . 7A . At 36 hours, the localized cellular uptake

was added to select wells and incubated for 1 hour at 37 ° C. ,

5 % CO2 ( pre - treatment procedure ). Following this one - hour
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incubation , 85 ug /well of fluorescently conjugated HALNPs

Software (NIH ). All protein quantification data was per

was added and the cells were further incubated for five
hours. Flow cytometry analysis was then used to compare

the delivery efficiency between HA pre -treated and non HA

pre - treated cells .
Example 17. Transfection of 21MT- 1 Cells

5

formed on at least three biological samples. M =mouse, and
Rb = rabbit.
Example 19. RNA Isolation and qRT-PCR
Total RNA was extracted from the 21MT- 1 metastatic

plates at a seeding density of 60,000 cells/well in 21MT- 1 10

breast cancer cell line at 72 hours post transfection using
Trizol ( Life Technologies) and following standard RNA
extraction
protocol. RNA quantity and quality was assessed
by a NanoDrop ( Thermo Scientific ) UV / VIS spectropho

were washed and the media was switched to 21MT- 1 Incom-

tometer, cDNA was made with iScript Reverse Transcription

21 MT- 1 cells were seeded onto 12 well tissue culture

Complete Media and left overnight. The next day the cells

plete Media . Following entrapment of miR125a - 5p by the

HA -LNP platform , quantification of internal miRNA cargo ,
and subsequent removal of un - entrapped miR by centrifu
gation, the HALNP -miR125a - 5p conjugate was filter ster
ilized through a 0.44 micron filter, and 50 pmol HALNP

entrapped miR125a - 5p was gently added to designated
wells
. In was
additionadded
, an analogous
amountwells
of HALNP
with no
miRNA
to neighboring
as a negative

15

Supermix for qRT -PCR ( Bio - Rad ) , and a RealPlex thermo
cycler ( Eppendorf) was used to create cDNA ( 5 min 25 ° C. ,
30 min 42 ° C. , 5 min 85 ° C. ) . Following cDNA creation ,

qRT -PCR was performed by using the SYBR Green Master

20

Mix (Life Technologies ), and a per - reaction use of 500 nM
of both the forward and reverse primers with 10 ng of
cDNA . The qRT-PCR was performed with a 40 cycle
amplification ( 95° C. for 10 seconds, 56° C. for 30 seconds,
and 72 ° C. for 30 seconds ) and a threshold intensity of 50
(during linear phase ). The primers used for the qRT-PCR

control, and two sample types of Lipofectamine 2000 (Life
Technologies, LF2K) were administered : 1 ) a low dose ( 50 analysis are as follows:
pmol ) of miR125a - 5p to compare to the HALNP system ;
and 2 ) a high dose positive control ( 150 pmol ) , both fol- 25
Human GAPDH :
lowing standard protocol per the manufacturer's instructions
( SEQ
for transfection . To further compare transfection efficiency
( R : 5 ' - AGG - GGC - CAT - CCA - CAG - TCT - TC - 3 ' ) ;
with LF2K , a 150 pmol HALNP - miR125a - 5p " high dose ”
( SEQ
was also used . Additionally, a scramble miR negative con
trol ( 150 pmol ) was encapsulated and delivered with the 30 (F : 5 ' - AGA - AGG - CTG - GGG - CTC - ATT - TG - 3 ' )
HALNP system to validate the specificity of the silencing
Human HER2 :
interaction . The delivery systems and controls were incu
cells were washed once with 1xPBS , supplemented with

fresh 21MT- 1 complete media , and placed in the incubator
( represented as time point = 0 hr).
Example 18. Western Blotting

ID NO : 2 )

( SEQ ID NO : 3 )
( R : 5 ' - TGA - TGA -GGA - TCC - CAA - AGA - CC - 3 ' ) ;

bated with the 21MT- 1 cells for five hours to mediate

transfection . Following the five hour incubation time , the

ID NO : 1 )

35

( SEQ ID NO : 4 )

( F : 5 ' - AAC - TGC - ACC - CAC - TCC - TGT - GT - 3 ' ) .

The AACt Method was used to calculate changes in gene
lyzed .

expression , and at least three biological samples were ana
40

Example 20. In Vitro Migration Assay
21MT- 1 cells were transfected as previously described
and plated into new 12 well plates as confluent monolayers.
by the scraping method . Western blotting was used to 45 Three vertical scratches were made per well and cell debris
determine the effect of miR125a - 5p transfection on the was washed away with 1xPBS prior to taking the time =0 h
21MT - 1 cell line protein expression levels . All proteins photos. Additional photos were taken at 24 h and 48 h time
besides ERK1 / 2 and phospho - ERK1 / 2 were tested and points. The cells were supplemented in complete 21MT- 1
probed on 7.5 % tris - glycine SDS PAGE homemade gels . media for the entire migration assay. ImageJ was used to
The ERK1/2 proteins were probed on 15 % homemade gels 50 quantify the scratch width (arbitrary units) changes at each
to resolve the 42 and 44 kDa double band . Coomassie blue
time point. A total of 27 scratch width data points were taken
reagent ( Thermo Scientific ) was used to quantify total for each sample type at each time point (3 scratches per
protein concentration and 10 ug total protein lysate was wellx3 pictures per scratchx3 biological duplicates per
loaded per lane. The primary antibody information used for sample type ).
all the proteins is as follows in order from smallest to largest 55
molecular weight: Anti -GAPDH (Millipore ; ABS16 ) 1 : 4000
Example 21. Model Drug System for Delivery to
Breast Cancer Cells
Rb, Anti -Phospho -ERK1 / 2 (Millipore; 05-797R) 1 : 1000 Rb ,
Anti- ERK1/ 2 clone MK12 (Millipore; 05-1152 ) 1 : 1000 M ,
Anti- Tubulin (Abcam ; ab44928 ), Anti -Phosphor-AKT
To investigate the relationship between CD44 expression
( Ser473) ( Millipore ; 05-1003 ) 1 : 1000 M , Anti - AKT /PKB 60 and HA as a possible targeting moiety to deliver LNPs , FD
Total protein was extracted at the 72 -hour time point from
the 21 MT - 1 cell line by standard protocol including RIPA
buffer induced cell lysis and protein solubilization followed

PH Domain ( Millipore; 05-591 ) 1 : 1000 M , Anti - CD44
( Abcam ; ab103552 ) , Anti -PI3K (Millipore ; 05-217 ) 1 : 1000
M , Anti -HER2 ( Abeam ; ab2428 ) 1 : 1000 Rb , and Anti-Ki-67
(Millipore; AB9260) 1 : 1000 , Rb . The secondary antibodies

was used as a model drug. FD is fluorescently tagged ,
impermeable to cell membranes, and can be polymerized to
a range of molecular weights to model a variety of thera
peutic molecules . Because the molecular weight of miRNA

used were Goat Anti -Rabbit - HRP (Santa Cruz, sc - 2030 ) 65 is typically in the range of 14-19 kDa , 20 kDa FD was used
1 : 5000 and Goat - Anti-Mouse -HRP (Santa Cruz; sc - 2031 ) as a model for miRNA encapsulation and intracellular
1 : 5000 . Protein bands were quantified by use of Image J delivery by the HALNP system . Three developmentally

US 11,202,838 B2
46
Example 23. In Vitro Breast Cancer Proliferation
and Migration

45

distinct human breast cell lines were used for nanoparticle
uptake analysis : 1 ) MCF10A ( normal mammary epithelial
cells ) , 2 ) SKBR3 (HER2 + invasive breast cancer cells ) , and
3 ) 21MT- 1 ( stable patient- derived metastatic breast cancer
Following validation that the HALNPs have an active
cells isolated from the metastatic pleural effusion ). In addi- 5 targeting mechanism as well as the ability to escape the
tion to representing three distinct stages of breast cancer intracellular endosome maturation pathway and achieve
progression , the three breast cell lines show differential cytosolic delivery, the HALNPs were used to encapsulate
expression profiles of CD44 , as shown in FIGS . 9A - 9C .

The cancer cell lines were first incubated with either the

free form FD drug ( i.e. , no HALNP ) or with an equivalent
amount of 20 kDa FD encapsulated inside HALNPs , and
compared the uptake qualitatively using a fluorescent micro
scope as shown in FIG . 9B , and quantitatively using a plate

human miR125a - 5p mimic and transfect 21 MT- 1 metastatic

breast cancer cells . The HALNP system was used to deliver

10 cells
50 pmol
/wellmiR125a- 5p to 21MT- 1 cells 24 hours after the
were seeded . The HALNP mediated transfection was

compared to Lipofectamine 2000 (LF2K) , a standard com
mercial transfection reagent, with 50 pmol miR125a - 5p for
potency comparison with HALNPs and at a high dosage of

reader
as shown
in FIG
9C. It was higher
observedin allthatthree
the 15 150 pmolmiR125a-5p as a positive control. Empty HALNP
fluorescence
intensity
was. significantly
particles were used both as a negative control and to confirm

cell types when FD was delivered using HALNPs as com
biochemical inactivity. Potent suppression of cellular
pared to free form delivery. Furthermore, the metastatic cell their
proliferation
observed at 72 hours post transfection as
line had the highest fluorescence intensity compared to other demonstratedwas
by phase contrast images , as shown in FIG .
cell lines indicating that the uptake of the LNPs was highest 20 11A . To further support these findings, an MTT assay was
in the metastatic cells . This experiment validated that the performed comparing HALNP delivered miR125a - 5p ( 50
strong correlation between uptake of the HALNP - FD par- pmol /well) and HALNP delivered scramble miR ( 50 pmol /
ticles and the degree of the breast tissue malignancy. Live well ) to validate the capacity and specificity of miR125a - 5p
confocal microscopy was also performed with the 21MT- 1 to reduce the hyper -proliferative phenotype of 21MT - 1 cells,
cell line following incubation with HALNP -20 kDa FD , as 25 as shown in FIG . 11B. A significant decrease in cellular
shown in FIG.9D , to show intracellular delivery of the cargo proliferation rate of over 15 % was observed at 72 hours post
was achieved . In addition , a competition assay with the transfection with miR125a - 5p as compared to the control
cells . The scramble miR had no effect on the metastatic cell
21MT- 1 cells via pre - treatment with excess HA before proliferation
.
a
addition of the HALNPs was performed , and a 55 % decrease 30 The effect rate
of
miR125a
- 5p on the migration potential of
in HALNP uptake was observed as shown in FIG . 9E .
the
metastatic
breast
cancer
was also examined due to
To further validate the targeting and subsequent prefer the connection between HER2cells
overexpression
and increased
ential uptake of the nanocarrier to CD44 positive cells , flow cellular motility ( see e.g. , Grothey et al , Oncogene
,
cytometry analysis was performed between 21MT- 1 and 19 : 4864 ; Balz et al , The Journal of Pathology, 2012, ,2000
227
MCF10A cells to determine the per cell uptake of HALNPs 35 234 ) . Following an analogous 72 - hour transfection period as:
fluorescently tagged with 0.15 mass % green fluorescent described above , scratches were made in confluent mono
cholesterol in the lipid bilayer as shown in FIG . 9F. An
and the wound healing potential (migration potential)
approximate four - fold increase in HALNP uptake was layers
of each sample type was analyzed as a time course study by
observed in the 21MT- 1 cell line over the MCF10A cell line
an inverted microscope as shown in FIG . 11C . The HALNP
on a per -cell basis , corroborating the targeting potential 40 miR125a
- 5p and LF2K high dose positive control both

observed in the FD uptake studies .

showed over a 50 % reduction in cellular migration as
compared to the control cells , while the LF2K 50 pmol dose

Example 22. Lysosomal Degradation and Cellular
Cytoplasm Dispersion

Because the RNAi pathway of gene silencing requires the
miRNA to be cytosolic, the localization of the HALNPs
following the CD44 mediated endocytosis event was investigated . To do so , the green fluorescent cholesterol tagged
HALNPs were analyzed using live confocal microscopy to
determine the cellular fate . 21MT - 1 cells were plated , incubated with tagged HALNPs , stained cellular lysosomes ( a
main degradation pathway for nanoparticles) red , and found
minimal co - localization between the lysosomes and the
HALNPs , as shown in FIG . 10A . In addition, it was found
that the HALNPs were homogenously dispersed in the
cellular cytoplasm , signifying endosomal escape . To validate that the HALNPs were cytosolic, a z - axis transformation was performed to construct a side profile view of the
cells , as shown in FIG . 10B ( XZ plane view : the bottom of
the XZ plane is the contact point between the cells and the
petri dish ). The nucleus was used as an internal reference
point to validate the nanoparticles were cytosolic and not
residing on the outer cellular membrane . In the z - axis
transformation analysis , the HALNPs also appeared uniform
in dispersion with virtually no co - localization with lysosomes .

showed a 16 % decrease and the HALNP control did not

statistically affect cellular migration. A three dimensional

45 graph depicting the change in scratch width as a function of
time in each sample type (FIG . 11D ) was created in con
junction with an Anova analysis ( FIG . 11E ) to clarify and
substantiate the experimental results . By reducing the poten
tial for cellular migration, the HA - LNP -miR125a - 5p thera
50 peutic system impedes a main driving force for metastasis
( see e.g. , Doyle et al , Current Opinion in Cell Biology, 2013 ,
25 :642 ).

55

Example 24. HER2 Gene Knockdown

21MT- 1 cells were transfected and qRT -PCR probing was
performed for the HER2 oncogene 72 -hours post transfec
tion as shown in FIG . 12. To directly compare the transfec
tion efficiency of the HALNP and commercially available
60 LF2K , both 50 and 150 pmol miR125a - 5p were delivered
using both delivery systems. At 72 h , a 40 % and 60 %
knockdown in the HER2 mRNA levels with 50 pmol and
150 pmol miR125a - 5p delivered via HALNPs , respectively,
was observed . Conversely, at 50 pmol miR125a - 5p no
65 knockdown was seen with LF2K and at 150 pmol only a
40% knockdown was achieved . To further confirm the
knockdown of the HER2 mRNA was due to miR sequence
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specificity, 21MT - 1 cells were transfected with 150 pmol
scramble miR delivered via HALNPs and no gene silencing

50 pmol miR125a - 5p as well as the empty HALNP had no
effect on Ki67 protein expression and cellular proliferation

effect was detected at 72 h .

rates .

Example 25. Silencing HER2 Protein in Metastatic

5

Example 26. MAPK Pathway

Breast Cancer Cells

To validate the application of the HALNP - miR125a - 5p as
a viable therapeutic for HER2 + metastatic breast cancer, the

The effect of miR125a - 5p transfection on the MAPK

pathway was also investigated. The MAPK pathway is vital
in cellular functions including proliferation , growth, and

effect of miR125a- 5p delivery on complex HER2 signaling 10 senescence (see e.g. , McCubrey et al , Biochimica et Bio

was investigated. 21 MT- 1 cells were transfected with HAL-

physica
( BBA) et—Molecular
Cell Research
, 2007 ,
1773 : 1263Acta
; Santarpia
al , Expert Opinion
on Therapeutic
Targets, 2012 , 16 : 103 ) . Transfection of 21MT- 1 cells with
miR125a - 5p resulted in aa 20% reduction of the phosphory
in HER2 levels was observed when transfected with the
lation of ERK1 /2 by delivery via HALNPs , and a 30 %
HALNP -miR125a - 5p system as compared to a 35 % reduc 15 reduction
in by the LF2K high dose positive control. This
tion with the LF2K high dose positive control as shown in data , coupled
the PI3K / AKT pathway confirmed that
FIG . 13A . Although this protein knockdown was less than the main two with
signaling
of HER2 were knocked
that of previous studies using this miRNA to target HER2 , down following HALNPcascades
mediated miR125a - 5p transfec
this
potent silencing effect was achieved without viralmedi- 20 tion. A comprehensive view of Western Blot analysis is
ated cellular transformation ( see e.g. , Scott et al , J. Bio . shown in FIG . 13A . In all analyses shown, the LF2K 50
Chem . 2007, 282 : 1479 ) , performed with a nanoparticle pmol and HALNP control induced no statistically relevant
system capable of in vivo application ( see e.g. Nishida et al , protein knockdown.
Clin . Cancer Res . 2011 , 17 : 2725 ) , and utilized an overall
25
low dose of miRNA compared to Lipofectamine.
Example 27. In Vitro Glioblastoma Assays
Because the two most prominent paths of signal trans
duction for HER2 are the mitogen activated protein kinase
The following general materials and methods were used
(MAPK ) and the phosphoinositide - 3 -kinase ( PI3K /AKT) for Examples 28-31 , describing targeted delivery of cargo to
pathways ( see e.g. Emde et al , Critical Reviews in Oncology / CD44 overexpressing glioblastoma cells .
Hematology, 2012 , Supplement 1 : e49) , and the fact that 30 Materials
For hyaluronic acid coated liposome nanoparticle cre
these pathways are commonly deregulated upon cancer ation
weight hyaluronic acid (HA) (~ 1.65
onset , both pathways were probed to elicit the influence of MDa , ,high molecular
1,2
Dipalmitoyl
-Glycero -3 - Phosphoetha
the HA - LNP -miR125a system on the HER2 downstream nolamine (DPPE ) , Cholesterol -(snCHOL
) , and 1 -ethyl-3-(3
signaling cascade as shown in FIGS . 13A - 13B .
35
dimethylaminopropyl
)
carbomiide
(
EDAC
purchased
The PI3K /AKT pathway is involved in cell survival, from Sigma Aldrich ( St. Louis , Mo. , USA)) . were
Additionally
,L
proliferation , migration , and angiogenesis (see e.g. , Balz et a - Phosphatidylcholine ( PC ) , Top Fluor fluorescently conju
al , The Journal of Pathology, 2012 , 227 : 234 ) and PI3K and gated cholesterol (FCHOL ) , and a mini - extruder apparatus
AKT activity are inherently coupled because AKT binds to were
purchased from Avanti Polar Lipids ( Alabaster, Ala . ,
the
product
of
PI3K
,
PIP3
,
leading
to
AKT
threonine
308
40
USA
)
.
For flow cytometry analysis , flow cytometry tubes
phosphorylation ( see e.g. Manning et al , Cell, 2007, 129 : were purchased from Becton Dickenson (Franklin Lakes ,
1261 ; Huang et al , Biochemical Society Transactions, 2009 : N.J. , USA) . For cell culture, all tissue culture petri substrates
37-217 ) . Accordingly, knockdown of PI3K was investigated were purchased from Fisher ( Waltham , Mass . , USA) .
to validate the silencing of initial downstream targets of Lipid Nanoparticle Fabrication and Hyaluronic Acid Surface
HER2 . Following a 72 -hour transfection period, a 35 % and 45 Decoration
40 % knockdown of the protein levels of PI3K from the
Multilamellar vesicles were made from PC , DPPE , and
HALNP mediated miR125a - 5p transfection and LF2K high CHOL in a 3 : 1 : 1 molar ratio and doped with 0.15 mass %
dose positive control respectively was observed . Because FCHOL ( as a tracker) by applying the dry lipid film tech
additional phosphorylation of AKT at serine473 is required nique, mechanically extruded to the nanoscale, and surface
for full AKT activation ( see e.g. , Manning et al , Cell , 2007 , 50 decorated with HA as described above ( see also , e.g. ,
129 : 1261 ; Huang et al , Biochemical Society Transactions, Hayward et al , J. Biomed . Nanotechnol. 2016 , 12 : 554-568 ;
2009 : 37-217 ) , this specific phosphorylation event was Hayward et al , Sci. Rep . 2015 , 5 : 14683 ) . For example,
investigated. The HALNP system achieved a 40 % knock- extrusion was performed in a stepwise manner at 65 ° C.
down of the phosphorylation of AKT at the lower concen- ensuring product homogeneity and a final lipid nanoparticle
NPs and the resultant effect of miR - 125a - 5p on HER2
protein levels was probed via Western Blot . A 30 % reduction

tration of 50 pmol while a concentration of 150 pmol was 55 (LNP) diameter in the 80-100 nm range. Following LNP
required to achieve a 60 % knockdown using Lipofectamine, purification via ultracentrifugation to remove any excess
indicating the higher efficiency of the LNP platform . A

lipid debris ( 1.5 hr, 135,000 g ) , the primary amine of the

downstream target of PI3K / AKT activation is Ki67 , a common proliferation marker that correlates to cellular prolif-

DPPE lipid head group was amide bonded to the carboxylic
acid group of EDC -activated HA to form HA decorated

Yerushalmi et al , The Lancet Oncology , 2010 , 11 : 174 ) .
Following transfection, a Ki67 protein knockdown of about
40 % was observed with the HALNP system compared to a

reagents and either 1 ) stored at 4 ° C. and used within 2
weeks of creation or 2 ) snap frozen and lyophilized as
described above and in Hayward et al , J. Biomed . Nano

results directly correlated with the reduction of cellular

were observed to be stable for over two months when stored

2

eration rates due to its presence during active phases of cell 60 LNPs (HALNPs) following standard crosslinking protocol.
cycle and sharp decline during rest cycles ( see e.g. , The HALNPs were then purified form excess crosslinking
50 % knockdown to the LF2K high dose control. These 65 technol. 2016 , 12 : 554-568 ) . Lyophilized HA coated particles

proliferation depicted by phase contrast imagery. The LF2K

at -80 ° C. To determine the effect of HALNP membrane
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fluidity on the kinetics of drug release , the molar ratio of 0.15 mass % FCHOL as a tracker were added to the cells at
cholesterol was varied from 20 to 25 % and a model thera- a concentration of 105 ug lipid per well and incubated for 3
peutic cargo , FITC tagged Dextran , was encapsulated into or 12 hours . Directly after this incubation time , the cells
the aqueous core of the HALNPs as described above and in were washed three times with sterile 1xPBS , trypsinized,
Hayward et al , J. Biomed . Nanotechnol. 2016 , 12 : 554-568 ) . 5 and measured for per cell and population wide fluorescence
Although the higher cholesterol formulation extended drug (ex . 495 , em . 520 ; 10,000 total events / read ). By reading
release profiles, this higher cholesterol content was found to control cells without the addition of HALNPs , a lower limit
reduce encapsulation efficiency . As a result, 20 mol % gating event was created to remove cell specific auto fluo
particles were used for the HALNP composition and glio rescence .
blastoma assays.
10 Confocal Microscopy
Table 4 shows the size and charge characterization of the
An Inverted confocal microscope (Olympus IX 81 ) at the

lipid nanocarrier, pre and post surface -modified with high
molecular weight HA used in assays for targeted delivery to
CD44 overexpressing glioblastoma cells .

15

TABLE 4
Hydrodynamic Polydispersity
Diameter

(nm)
LNP

95.0 + 0.7

Zeta

Index
( PI)

Potential

0.032
0.157

-5.74 + 2.24

(mV )

UNL Microscopy Core Research Facility was used for the
following experiments :
1 ) Confocal of the Fluorescently Tagged HALNPs
FCHOL doped HALNPs were diluted to 55 ng /ml in
1xPBS and the solution was viewed at 100x magnification
with optical zoom using a cover slip ( ex . 495 , em . 520 ) .
2 ) Quantitative HALNP Uptake Between the In Vitro
Brain Model

20

Cort Astro , Cereb Astro, MG , A172 , U251 , and U87MG

cells were seeded at 230,000 cells per 35 mm glass bottom
126.6 + 5.62
-23.64 + 1.49
HALNP
dish from Mattek (Ashland, Mass . , USA) overnight to
promote cell attachment. The next morning, 1.58 mg /mL
Dynamic Light Scattering and Zeta Potential Characteriza- HALNP was added per dish and incubated for 3 hours .
tion
25 During the final half hour of the incubation , cellular nuclei
Hydrodynamic diameter and zeta potential of the LNPs were stained with Hoerscht ( Thermo Scientific ) following
and HA coated LNPs ( i.e. , HALNP or HA - LNP ) was mea- stated protocol. Subsequent to the staining procedure, each
sured using a Brookhaven NanoBrook ZetaPALS zeta dish was washed 3x with sterile 1xPBS and kept in HEPES
potential and dynamic light scattering instrument (Holts- buffered media without phenol red during the confocal
ville , N.Y., USA) . The nanoparticle size was measured as an 30 visualization . A constant laser intensity was used to take
intensity averaged distribution using a scattering angle of photos at 20x and 60x for each cell type for a quantitative
90 ° . The Smoluchowki model was utilized to calculate the measurement of HALNP uptake.
zeta potential from mobility measurements . All measure3 ) Lysosomal Co - Localization
Cort Astro , MG , and A172 cells were seeded at 230,000
ments were performed in 0.05xPBS ( pH 7.4 ) at 25 ° C.
Cell Cultures
35 cells per 35 mm glass bottom dish from Mattek overnight to
Primary cortical ( Cort) and cerebellum (Cereb ) astrocytes promote cell attachment. The next morning, 1.58 mg /mL
were prepared from 1-2 day - old Charles River ( Wilmington, HALNP was added per dish and incubated for 5 hours, and
Mass . , USA) Sprague- Dawley rat pups according to stan- the intracellular lysosomes and nuclei were stained accord
dard protocols ( see e.g. , Natarajan et al , PLOS One ; ing to protocols described above and in Hayward et al , J.
10 : e0134541 ) . Briefly, the Cort and Cereb brain regions 40 Biomed . Nantechnol. 2016 , 12 : 554-568 . Following incuba
were isolated, digested with trypsin and DNase , filtered tion , the cells were washed and visualized at 100x . Z - axis

through a 70 micron filter, centrifuged, and suspended in slices were merged to display the occurrence of HALNP
complete culture media prior to seeding. The Cort and Cereb lysosome co - localization in each cell type.
Astrocytes were cultured in DMEM / F12 supplemented with
4 ) Z - Axis Transformation with A172 Cells
10 % FBS and 1 % PS from Life Technologies (Grand Island, 45 A172 cells were seeded at 230,000 cells per glass bottom
N.Y., USA) .
plate , incubated with 1.58 mg/mL HALNP for five hours,
Mouse microglia were grown in macrophage serum free and the lysosomes and nuclei were stained . A Z - axis trans
media containing L - glutamine and supplemented with 10 % formation was then performed ( 100x with optical zoom)
FBS and 1 % PS . Additionally, recombinant mouse granu- using the stained cell nucleus as an internal reference point.
locyte macrophage colony stimulating factor ( GM - CSF ) 50 From this analysis , an XZ and YZ plan were constructed to
from Life Technologies was added to each seeded flask at a directly visualize cytoplasmic HALNPs .

concentration of 10 ng /ml and replenished every 3 days.

Western Blot

A172 ( ATCC: CRL1620 ) human glioblastoma cell line
Total protein was extracted from Cort Astro , Cereb Astro ,
was grown in DMEM / F12 supplemented with 10 % FBS and MG , A172 , U251 , and U87MG cells cultured on standard
1 % PS . U251 ( Sigma ) human glioblastoma astrocytoma and 55 TCPS surfaces by RIPA buffer induced cell lysis and protein

U87MG (ATCC : HTB14 ) human grade IV astrocytoma/ solubilization followed by the scraping method . Western
glioblastoma cell lines were grown in MEM media supple- blotting was used to determine the expression of the cell
mented with 10 % FBS , 1 % PS , 1 % NEAA , and 1 mM surface receptor CD44 in each of the six brain cells . BCA
Sodium Pyruvate ( Thermo Scientific ; Waltham , Mass . , protein quantification kit from Abcam ( Cambridge, Mass . ,
USA) .
60 USA) was used to quantify total protein concentration, 25 ug
Flow cytometry
total protein was loaded per lane, the blot was run on a 7.5 %
Flow cytometry was performed using a FACSCantoII tris -glycine SDS PAGE homemade gel , the membrane was
from Becton Dickenson ( Franklin Lakes, N.J. , USA) . Each probed for CD44 ( Abcam ; ab24504 ) , and protein bands
of the six cell types of the in vitro brain model were seeded were developed and quantified by use of a LI - COR (Lincoln ,
at a density of 100,000 cells per well in a 12 well plate layout 65 Nebr. , USA) Odyssey FC and Image Studio Lite ver . 5.0
and allowed to incubate overnight to facilitate cell attach- software, respectively. GAPDH (Millipore ; ABS16 ) expres
ment. After incubation , HALNPs fluorescently doped with sion was measured as a normalization control for loading.
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Saturation of CD44 Receptor ( Competition Assay )
Cort Astro, Cereb Astro, MG , A172 , U251 , and U87MG
cells were seeded overnight at a density of 100,000 cells per
well in a 12 well plate . The next morning, 250 ug of HA was
added to select wells and incubated for 1 hour at 37 ° C.
Following this pre - treatment procedure, 105 ug fluorescently doped HALNPs were incubated with the cells for
three hours and then flow cytometry analysis was used to
directly measure the difference in per cell fluorescence
between the HA pre - treated samples and non HA -pretreated
samples (of analogous HALNP incubation time and concentration ).
DOX Potency Assay
Encapsulation of DOX into HALNPs Doxorubicin
( DOX ) was encapsulated inside the aqueous core of the
HALNPs as described above and in Hayward et al , Sci. Rep .
2015 , 5 : 14683 . Briefly, a vial of lyophilized HALNPs (0.5
mg lipid) was brought to room temperature , and rehydrated
with 1 /10th its original pre -lyophilized volume of 0.05xPBS
containing 250 ug DOX . Following a thirty minute incubation time to allow for lipid membrane re -assembly, the vial
was brought back to its full pre - lyophilized volume with
1xPBS and ultracentrifuged to remove non -encapsulated
DOX ( 140,000 g , 4 ° C. , and 1.25 hr .). The auto - fluorescent
property ofDOX was then used to determine the entrapment
payload . A standard curve consisting of a? known amount of
DOX was compared to 0.1 % triton X - 100 permeabilized
HALNPs to determine the total encapsulated DOX . A final

were utilized . Specifically, three GBM cells lines were
selected to obtain results spanning different source donors as
well as to probe the potential of treating GBM cells with
varying phenotypical properties such as invasive and non
tumorigenic (A172 cells ) , non - invasive and slightly tumori
genic (U251), and invasive and highly tumorigenic
(U87MG ) ( see e.g. , de Ridder et al , Acta Neuropathol, 1987 ,
72 : 207-213 ).
The targeting capacity of HA was directly assessed in
GBM cells along with MG and astrocytes using flow cytom
etry analysis as shown in FIG . 14A . Flow cytometry was
selected due to its capacity to examine uptake simultane
ously in both a population wide , as shown in FIG . 14B , and
per cell basis , as shown in FIG . 14C . Prior to analysis, all six
cell types were seeded at low density to ensure the uptake
data acquired was indicative of per -cell behavior (Supple
mentary FIG . 3 ) . Following a three hour incubation time
with the HALNPs, the cerebellum and cortical astrocytes
exhibited 29.3 % and 32 % positive populations for HALNP
uptake, and a 10 and 6.7 fold change in per cell fluorescence,
respectively. At the same time point, the MG cells had a
37.7 % positive population, and aa 14.5 fold change in per cell
fluorescence, while the A172 , 251 , and U87MG GBM
cells achieved 77.7 % , 34.5 % , and 52.5 % positive popula
tions with 153.4 , 87.3 , and 133.3 fold change in per cell
fluorescence , respectively. This significant difference in
HALNP uptake between the glial ( astrocytes and microglial)
and the GBM cells was further corroborated by quantitative

5
10
15

20

25

lipid to DOX mass ratio of 2.88 to 1 was achieved with a confocal microscopy at the analogous three hour time point,
69.4 % encapsulation efficiency. These purified DOX con- 30 as shown in FIG . 14D .
taining particles are referred to as HALNP - DOX .
Flow cytometry was also performed after a 12 -hour
Cort Astro , MG , and A172 cells were seeded in aa 48 well incubation with HALNPs to show if the differential cell
plate at density of 35,000 cells per well and incubated uptake patterns were transient or long lived via a preferential
overnight to facilitate cell attachment. The next day follow- mechanism . Following this incubation time , the cerebellum
ing validation of homogenous cell attachment, DOX in its 35 and cortical astrocytes had a 57.8 % and 52.9 % positive
free form ( i.e. , not associated with a nanocarrier ) or population and a 43.8 and a 28.6 fold change in per cell
HALNP - DOX were added to select wells in a concentration fluorescence, respectively. Furthermore , the MG cells
range of 0 to 10 ug /mL and incubated for an additional 24 reached a 57.7 % population and a 54.3 fold change in
hours.
fluorescence, while the A172 , U251 , and U87MG GBM
To determine the effect of free DOX and HALNPDOX on 40 cells attained 84.1 % , 61.8 % , and a 55 % positive populations
the cell viability of Cort Astro , MG and A172 cells , an MTT with 314.6 , 233.3 and 161.7 fold change in per cell fluo
assay was utilized as described herein to calculate the lethal rescence, respectively. These experiments demonstrated the
concentration to kill 50 % of the cells ( see also , e.g. , Hay- potential of employing HALNPs for targeting GBM cells . In
ward et al , Sci .Rep. 2015 , 5 : 14683 ; Wilson et al , Nanoscale, addition , the results obtained indicate that HA may bind with
2015 , 7 : 18477-18488 ; Natarajan et al , PLOS One, 2015 , 45 the GBM cells differently than the healthy glial cells to

10 : e0134541 ) . Following the 24 hour DOX incubation time ,
the medium of the cells was aspirated, and sterile 5 mg /mL

facilitate preferential intracellular delivery.
Example 29. Differential Expression of CD44

MTT working solution was added and incubated for 2 hours
at 37 ° C. The cells were then lysed with acidified IPA and the
Facilitates Active Targeting of Glioblastoma Cells
absorbance of the produced formazan crystals was measured 50
using a Beckman Coulter AD340 plate reader ( Indianapolis,
CD44 is a cell surface receptor which can be used for
Ind ., USA) . Percent viability was determined by normaliza- targeted therapy for a range of cancer types ( see e.g. , Platt
tion of the 570/620 absorbance ratio to the control untreated et al , Mol. Pharm . 2008 , 5 : 474-486 ) and has been shown to
cells and positive control dead cells ( ethanol treated ).
play a role in regulation of macrophage phagocytosis and
55 inflammation pathways ( see e.g. , Vachon et al , Blood , 2007 ,
Statistical Analysis
The difference between experimental groups was inves- 110 : 4492-4502 ; Vivers et al , Clin. Sci. ( Lond ). 2002 , 103 :
tigated by a one - way analysis of variance ( ANOVA ) and by 441-449 ) . To investigate if the preferential uptake of HAL
a subsequent Turkey's multiple comparison test in Sigma NPs to glioblastoma ( GBM) cells over astrocytes and micro
Plot Software . For statistical analysis of all data , p <0.05 was glia ( MG) cells is driven by CD44 western blot was
regarded as the lowest acceptable threshold for significance. 60 performed to quantify total CD44 protein levels in all six
cells types, as shown in FIG . 15. From this analysis it was
Example 28. Targeted Delivery to CD44
found that CD44 is expressed lowest in both cerebellum and
Overexpressing Glioblastoma Cells
cortical astrocytes, higher in the GBM cells , and highest in
the MG cells . By using the cerebellum astrocytes as a
To test HA driven active targeting for GBM (glioblas- 65 comparison baseline for CD44 expression, it was found that
toma ) therapy, cell cultures consisting of primary rat astro- cortical astrocytes, MG , A172 , U251 , and U87MG GBM
cytes, primary mouse microglia cells , and human GBM cells cells had a 2 , 5 , 3.3 , 3.8 , and 3.9 fold higher expression,
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respectively. This data correlates with recent findings that
CD44 expression is increased in glioma cells as compared to

nm in size , -21.19 + 5.2 mV in charge, and had a PI of 0.241.
The three cell types were seeded overnight and then a
potency assay was performed the next morning over a DOX

healthy astrocytes ( see e.g. , Asher et al , Exp. Cell Res. 1992 ,
203 : 80-90 ; Yoshida et al , Pathol. Int. 2012 , 62 : 463-470) .

A saturation experiment was then performed to precisely 5s range ( encapsulated DOX ) of 0 to 10 ug /mL. Following the

block the CD44 receptor to discern if the increase in total
CD44 expression translated to a higher uptake of the HALNPs , as shown in FIG . 16. Each of the cell types was
pre -treated with excess HA prior to the addition of the

24 hour incubation time , a standard MTT viability assay was
used to determine the lethal concentration to kill 50% of the

samples . The percent difference in uptake was then used as
a quantitative measure as to the capacity of each specific cell

the cortical astrocytes, and nearly 3 fold lower than the LC50
for the MG cells . Specifically, the LC50 values were found

cell population (LC50 ) , as shown in FIG . 18. This assay

HALNPs
, and then the per -cell fluorescence was directly 10 demonstrated that the LC 50 of HALNP encapsulated DOX
compared between the pre - treated and non -pretreated for the A172 cells was nearly 5 fold lower than the LC50 for

type to employ CD44 - HA receptor endocytosis of the HAL

NPs. From this analysis it was found that both cerebellum 15 toDOXbe for0.511the:0.039
, 0.317+0.048, and 0.114+0.010 ug /ml
Cort astro , MG , and A172 cells , respectively,

and cortical astrocytes do not internalize HALNPs via a
CD44 driven route, and thus any uptake into these cells is
facilitated by nonspecific interactions. Similarly, HA pre
treatment did not significantly influence HALNP uptake in
MG cells although they exhibited the highest total CD44
expression . In contrast, A172 , U251 , and U87MG GBM
cells were found to significantly employ CD44 stimulated
uptake yielding a percent difference in per- cell fluorescence

as shown in Table 5. These results show the significant
advantage of employing HA as an active GBM targeting

20 ligand .

To further probe the specificity of HA mediated targeting,
a 24 - hour potency assay was performed with the three cells
types utilizing DOX in its free form (i.e. , not conjugated

of 36 % , 48 % , and 76 % , respectively.

25

Example 30. CD44 Stimulated Uptake of HALNPs

Leads to Endolysosomal Escape in GBM Cells
To investigate the intracellular distribution of HALNPs as
a function of CD44 receptor employment, live cell confocal 30
microscopy was performed to visualize the HALNP -lyso
some co - localization patterns to directly test if cells that

exploit CD44 driven uptake (e.g. , GBM cells ) have different

with a nanocarrier ). It was found that DOX was less potent
in the cortical astrocytes and most potent in the A172 cells .
LC50 data for Free DOX and HALNP - DOX are shown
below in Table 5 .

TABLE 5

Potency assay with doxorubicin (DOX ) LC50 values
( ug/ml) following the 24 -hour incubation time

HALNP intracellular fate than that of cells that do not

Cell

readily utilize CD44 (e.g. , astrocytes, MG) . For this analy- 35
sis , cortical astrocytes , MG , and A172 as representative cells

Cort Astro
MG

Free DOX

HALNP - DOX

0.322 + 0.053
0.267 + 0.050
0.193 + 0.030

0.511 + 0.039
0.317 + 0.048
0.114 + 0.010

A172
were selected for each cell type, and incubated the cells with
HALNPs for five hours prior to confocal investigation.
Using high magnification confocal microscopy and z axis
slicing as shown in FIG . 17A , it was observed that cortical 40 This experiment also validated the targeting capacity of
astrocytes and MG cells displayed extensive HALNP co- HA . For example , by comparing the HALNP - DOX LC50 to
localization with lysosomes . The A172 cells had signifi- the free DOX LC50 for each specific cell type, the therapeu
cantly less HALNP co - localization with lysosomes follow- tic influence of specificity was quantified. For the cortical
ing intracellular delivery . To further authenticate that the astrocytes, the LC50 value significantly increased by 59 % by
HALNPs achieved cytoplasmic escape in the A172 cells 45 utilizing the HALNP system over free DOX . Similarly, the
following CD44 driven uptake, confocal microscopy was LC50 increased by 19 % due to delivery of DOX encapsu
then performed with z - axis transformation as shown in FIG . lated in the HALNPs system to the MG cells . These results
17B . This technique allowed for the direct visualization of exemplify that the HALNP nanoparticles are not readily
HALNPs in comparison to an internal reference frame ( e.g. , internalized into healthy glial cells , and thus the HALNP
the cell nucleus) to better show that the HALNPs achieved 50 nanocarrier may reduce the chance of offsite toxicity for
homogenous cytoplasmic distribution with minimal lyso GBM therapy. The LC50 value also decreased significantly
somal co - localization . The confocal analysis results indicate
41 % for the A172 GBM cells via employment of the
that the combination of preferential uptake and lysosomal by
conjugates. This assay confirmed that the HALNP
evasion in GBM cells as opposed to the non - specific uptake HALNP
conjugate
increases the overall efficacy and safety of che
and lysosomal co - localization of healthy glial cells may lead 55
to enhanced potency and reduced offsite toxicity for HALNP motherapeutic GBM therapy.
facilitated GBM therapy.
Other Embodiments
Example 31. Delivery Selectivity and Efficacy
60
It is to be understood that while the invention has been
The therapeutic potential of HA as a targeting ligand for
described
conjunction with the detailed description
GBM treatment was tested by encapsulating doxorubicin thereof, theinforegoing
is intended to illustrate
into the HALNPs and performing a 24 - hour potency assay and not limit the scope ofdescription
the invention, which is defined by
with cortical astrocytes , MG , and A172 cells as described 65 the scope of the appended claims . Other aspects , advantages,
above in Example 27. A Lipid : DOX mass ratio of2.88 :1 was and modifications are within the scope of the following
achieved and the final DOX loaded particles were 167.829.2 claims .
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SEQUENCE LISTING
< 160 > NUMBER OF SEQ ID NOS : 4

< 210 > SEQ ID NO 1
< 211 > LENGTH : 20
< 212 > TYPE : DNA

< 213 > ORGANISM : Homo sapiens
< 400 > SEQUENCE : 1
aggggccatc cacagtcttc

20

< 210 > SEQ ID NO 2
< 211 > LENGTH : 7
< 212 > TYPE : DNA

< 213 > ORGANISM : Homo sapiens
< 400 > SEQUENCE :

2

agaaggc

7

< 210 > SEQ ID NO 3
< 211 > LENGTH : 20
< 212 > TYPE : DNA

< 213 > ORGANISM : Homo sapiens
< 400 > SEQUENCE :

3

tgatgaggat cccaaagacc

20

< 210 > SEQ ID NO 4
< 211 > LENGTH : 20

< 212 > TYPE : DNA

< 213 > ORGANISM : Homo sapiens
< 400 > SEQUENCE : 4

aactgcaccc actcctgtgt

20

6. The composition of claim 1 , wherein the liposome
40 comprises a hydrophilic core and a hydrophobic lipid
1. A composition comprising:
i ) one or more hyaluronic acid conjugated liposomes ; and bilayer.
7. The composition of claim 1 , wherein the liposome
ii ) a polyelectrolyte multilayer;
further
comprises one or more therapeutic agents .
wherein the hyaluronic acid is covalently bonded to the
8.
The
composition of claim 6 , wherein each of the
surface of the liposome ;
therapeutic agents is independently localized in the hydro
and wherein the one or more hyaluronic acid conjugated 45 philic core or hydrophobic lipid bilayer of the liposome .
liposomes are deposited onto the polyelectrolyte mul
9. The composition of claim 1 , wherein the liposome
tilayer.
further comprises a fluorescently tagged lipid .
2. The composition of claim 1 , wherein the polyelectro10. The composition of claim 1 , wherein the liposome
lyte multilayer comprises one or more independently 50 further comprises a targeting moiety .
selected polycationic polymers.
11. The composition of claim 10 , wherein the targeting
3. The composition of claim 1 , wherein the polyelectro- moiety is conjugated to the hyaluronic acid .
lyte multilayer comprises one or more independently
12. The composition of claim 1 , further comprising an
selected polyanionic polymers.
additional polyelectrolyte multilayer.
4. The composition of claim 3 , wherein at least one of the
13. The composition of claim 1 , further comprising
polyanionic polymers is poly (sodium styrene sulfonate ) 55 substrate selected from the group consisting of a medical
What is claimed is :

2

( SPS ) .
5. The composition of claim 1 , wherein the polyelectro

lyte multilayer comprises from about 2 to about 10 mono

layers of poly - L - lysine (PLL ) and from about 2 to about 10
monolayers of poly ( sodium styrene sulfonate ) ( SPS ) .

device, a tablet, a capsule , a bandage, a gel , and a nanopar
14. The composition of claim 2 , wherein at least one of
the polycationic polymers is poly - L -lysine ( PLL ) .
ticle .
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